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Abstract

CONDITIONAL CARDIAC-SPECIFIC AKAP13 KNOCKOUT INDUCES SEX
DEPENDENT BIVENTRICULAR DILATED CARDIOMYOPATHY WITH
SARCOMERIC AND MITOCHONDRIAL DEFECTS
By K. Maravet Baig-Ward, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2016

Major Director: Dr. James H. Segars, MD
Adjunct Professor, Biochemistry and Molecular Biology

Heart disease is a complex and heterogeneous disease. Notably, studies have
demonstrated gender differences in the expression and types of cardiovascular disease,
such as dilated cardiomyopathy (DCM), a major underlying cause of heart failure.
Previously we showed that loss of A-Kinase Anchoring Protein 13 (Akap13), a unique
proto-oncogene and estrogen receptor modulator, resulted in enlarged embryonic hearts,
defective cardiac sarcomere formation, and embryonic lethality in mice. Data have also
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xv
shown cAMP-dependent Protein Kinase A (PKA) to be involved in DCM
pathophysiology. Given the established role of AKAP13 in cell signaling, its ability to bind
and modulate ligand-activated nuclear hormone receptors and transcription factors, and its
association with actin and other cytoskeletal components, we hypothesized that a
functional AKAP13 protein was required for cardiomyocyte function in the adult
heart; defective function of AKAP13 could promote DCM. To this end, we established
an inducible, cardiac-specific Akap13 conditional knockout (Akap13cKO) mouse model
using a Cre-lox recombination strategy with two separate Cre-recombinase expressing
mouse models (α-MHC-MerCreMer and Tnnt2-rtTA; TetO-Cre).
Cardiac functional examination of Akap13cKO mice revealed significant
biventricular dilated cardiomyopathy with compensatory hypertrophic remodeling of the
left ventricle and left atrial enlargement, decreased left and right ventricular systolic
function, and abnormal left ventricular diastolic function. Of note, female Akap13cKO mice
displayed a more pronounced cardiac phenotype and were more likely to die postrecombination.

CHAPTER1: Introduction to AKAP13

Introduction
Cells process a vast array of diverse stimuli and differentiate a multitude of signals
based on multiple factors, including the cells’ internal and external milieu. Cyclic
adenosine monophosphate (cAMP), a commonly used, generic second messenger, is
involved in many, and often disparate, signaling pathways. A-Kinase Anchoring Proteins
(AKAPs) rectify cAMP signaling pathways by tethering cAMP-dependent Protein Kinase
A (PKA) to sub-cellular microdomains, such as organelles and other membranes
(Colledge, 1999) (Welch, 2010). Within these sub-cellular niches, AKAPs act as engaged
scaffolding proteins or “signaling centers,” confining PKA, or other signaling enzymes,
closer to their biological substrates, downstream signaling enzymes, supplemental
molecules, and co-factors. Notably, AKAP13, found on human chromosome 15q25.3 and
mouse chromosome 7D2 (Pruitt, 2013), is the only known AKAP with Guanine Nucleotide
Exchange Factor (GEF) activity and the ability to modulate nuclear hormone receptors
such as Estrogen Receptors α and β (ER α and ER β) (Rubino, 1998) (Driggers, 2001).
A-Kinase Anchoring Proteins (AKAPs) are essential signaling pathway rectifiers.
As a family, AKAPs share a common function: to bind and sequester cAMP-dependent
Protein Kinase A to discrete subcellular microdomains thereby enhancing downstream
signaling to PKA targets, and affecting gene expression (Wong, 2004) (Colledge, 1999).
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(Fig.1.1). It is hypothesized that these sub-cellular microdomains may be niches with
transiently increased levels of cAMP (Scott, 2010) (Bacskai, 1993) (Hempel, 1996).
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Figure 1.1| AKAPs in cell signaling. AKAPs have significant roles in cell signaling from
the membrane to the nucleus. AKAPs often associate with organelles and other cellular
components to rectify signaling pathways for spatiotemporal fidelity (modified from:
Wong, 2004).
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While AKAPs have a common function, they are structurally heterogeneous except for a
conserved 14-18 amino acid residue amphipathic helix (Baisamy, 2005) (Welch, 2010).
This helical region anchors Protein Kinase A. AKAPs also act as scaffolding proteins; they
can bind a variety of enzymes and associated substrates, both directly and indirectly, to
enhance signal transduction for timely action by the cell (Welch, 2010) (Mauban, 2009).
To date, there are more than 50 reported AKAPs; this number includes AKAP splice
variants (Carnegie, 2009) (Welch, 2010). AKAP13, also known as Brx and AKAP-Lbc, is
unique. In addition to classic AKAP function, tethering PKA to sub-cellular locations and
acting as a scaffolding protein, AKAP13 contains a Rho- Guanine Nucleotide Exchange
Factor (GEF) activity domain and binds to other signaling proteins including ligandactivated nuclear receptors (Rubino, 1998) (Diviani, 2001) (Fig. 1.2). GEFs, such as Epac,
are known to refine cAMP signaling (Pereira, 2007). Specifically, AKAP13 has been
shown to bind to nuclear receptors such as Estrogen Receptors (ER), retinoid X receptor
(RXR), thyroid hormone receptor (THR), peroxisome proliferator-activated receptor
(PPAR) and cAMP response element binding protein (CREB) (Rubino, 1998) (Driggers,
2001). Since AKAP13 has characteristic AKAP activity as well as Rho-GEF activity and
the ability to bind nuclear hormone receptors, it is essential that pathways involving
AKAP13 are tightly regulated and serve to promote cellular actions that are regulated both
spatially and temporally.
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Figure 1.2| Guanine Nucleotide Exchange Factor Activity. Guanine Nucleotide Exchange Factor
Activity (GEF) facilitates GTP-exchange on small G-Proteins. RhoA (GTPase) is activated with
the binding of GTP. GTPase Activating Proteins (GAPs) and Guanine Nucleotide Dissociation
Inhibitors (GDIs) affect the GDP and GTP binding state of the small G-protein.
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Initial characterization of AKA P13: Brx
Previous in vitro studies demonstrated the presence of an auxiliary protein that
bound the retinoid x receptor (RXR) and demonstrated involvement in the inhibition of
estrogen-responsive genes (Segars, 1993). These findings led to the hypothesis that an
auxiliary protein(s) also involved in estrogen-responsive breast cancer in vivo (Anzano,
1994) (Rubino, 1998). To this end, a breast cancer expression library was probed using a
cloning strategy that took advantage of the unknown auxiliary protein’s ability to bind
RXR. From this, a novel cDNA was isolated. Further analyses identified the novel
auxiliary protein to be the smallest and first AKAP13 gene product fully characterized, the
170kDa protein often referred to as Brx: breast cancer nuclear receptor-binding auxiliary
protein (Rubino, 1998). This isoform was found to directly associate with Estrogen
Receptor α (ER α) as exhibited by far-Western analysis (Rubino, 1998). Northern blot
analysis suggested that AKAP13 gene products were highly expressed in reproductive
tissues including tissues from the ZR 75-1 breast carcinoma cell line (Rubino, 1998). Due
to Brx’s presence in reproductive tissues, ability to bind nuclear hormone receptors via the
LXXLL (specifically LYELL) domain including ERs (Rubino, 1998) (Driggers 2001), and
the role of estrogen in some forms of breast and endometrial cancers, our group, and others
continued to pursue this isoform’s role in estrogen-responsive tissues. More recently,
AKAP13 has also been shown to bind Progesterone Receptor (PR) and the Vitamin D
receptor (VDR) among others (unpublished data).
In 2006, Wirtenberger and colleagues revealed a genetic polymorphism
(Lys526Gln) in AKAP13 with statistically significant association with familial breast
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cancer (OR=1.58, 95% CU=1.07-2.88). This single nucleotide polymorphism (SNP) was
found to be even more significantly linked to high-risk familial breast cancer (OR=1.85,
95% CI= 1.19-2.88). These data suggested that women with the AKAP13 Lys526Gln SNP
if diagnosed with breast cancer, were more likely to have high-risk breast cancer
(Wirtenberger, 2006).
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Functional and structural regions within AKAP13
AKAP13 is a unique cAMP-dependent Protein Kinase A Anchoring Protein
(AKAP) member of the Dbl family of oncoproteins (Rubino, 1998). As the name suggests,
AKAP13 acts to bind and sequester PKA in order to bring it closer to its biological
substrates (Michel and Scott, 2002). While AKAP13 can bind other isoforms of PKA, such
as type I PKA, it preferentially binds type II PKA (Diviani, 2004). Additionally, AKAP13
contains a single Dbl Homology domain (DH) with a single, flanking Pleckstrin Homology
domain (PH). Together these domains comprise the Guanine Nucleotide Exchange Factor
(GEF) activity region of the protein (Rubino, 1998) (Wirtenberger, 2006). While AKAP13
as a whole has not been crystallized, the GEF domain has been crystallized (Fig. 1.3)
(Azeez, 2014). This characteristic is shared by other oncogenic Dbl family members, such
as Lbc. AKAP13 is often reported as AKAP-Lbc in the literature because of the shared
sequence homology. AKAP13 has also been reported as a truncated form of Ht31 and has
even been called Ht31 (Klussmann, 2001). This, however, is not the case. Ht31 is a partial
cDNA is that likely a truncated form of AKAP13, and not vice versa. Therefore, AKAP13
is the preferred, and more accurate, name.

24

Figure 1.3| AKAP13 transcripts and Guanine Nucleotide Exchange Factor (GEF)
crystal structure. a) AKAP13 is alternatively spliced. Some of the more common
transcripts are depicted above. b) The RhoA and AKAP13 complex is depicted in
structural form. RhoA is depicted with red α-helices and yellow β-strands. AKAP13 DH
domain is depicted by the blue α-helices, and the PH domain is depicted by the green αhelices and β-strands (modified from: Azeez, 2014).
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It has been reported by our laboratory and others that AKAP13 is a RhoA-specific
GEF (Diviani, 2001) (Mayers, 2010). AKAP13’s GEF domain may have modest activity
with Rac and Cdc42 (Rubino, 1998) (O'Connor, 2012). However, AKAP13 also interacts
with small GTPases, such as Cdc42, in other capacities (Rubino, 1998).
AKAP13 Rho-GEF activity is regulated by the homodimerization of the AKAP13
carboxyl terminus (Baisamy, 2005). Similarly, AKAP13 has two putative 14-3-3 binding
sites; PKA bound to AKAP13 can phosphorylate serine residues within the 14-3-3 binding
sites thereby recruiting 14-3-3, and inhibiting AKAP13’s Rho-GEF activity (Diviani,
2004; Baisamy, 2005). Therefore, it is hypothesized that AKAP13 is maintained in a basal,
resting state through homodimerization of the carboxyl terminus and binding of 14-3-3
(Baisamy 2005). Binding of dimeric 14-3-3 prevents RhoA association with AKAP13
(Baisamy, 2005; Diviani, 2004). However, 14-3-3 only functions as an inhibitor of RhoGEF activity when AKAP13 is in an oligomeric state (Baisamy, 2005). With appropriate
activating stimuli, such as LPA or thrombin, the α subunit of the Gα12 signaling molecule
stimulates AKAP13 Rho-GEF activity (Diviani, 2001), preventing 14-3-3 binding, and
thereby assisting in the transformation of AKAP13 from a basal, resting state into a
multimolecular signaling rectifier. PKA acts as an inhibitor of RhoA and serum response
factor (SRF) and activator of cAMP-response element binding protein (CREB) (Sauzeau,
2000) (Ellerbroek, 2003). Conversely, RhoA activates SRF and therefore induction of
serum response element (SRE) driven genes, many of which are implicated in heart disease
(Mayers, 2010) (Seeger, 2010) (Montaner, 1999). Consequently, AKAP13 is central to the
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balance between CRE responsive genes and SRE responsive genes depending on the
physiologic and temporal needs of the cell including the developmental stage (Fig. 1.4).
As an active, modular protein platform, AKAP13 integrates upstream factors with
downstream signaling to affect gene expression and cell response (Rubino, 1998). In order
to do this, AKAP13 must bind or interact with an assortment of proteins with often
disparate family linkages. One such family is the Nuclear Hormone Receptor (NHR)
family, specifically Estrogen Receptor (ER) α (Rubino, 1998) and Estrogen Receptor (ER)
β (Driggers, 2001). AKAP13’s novel and somewhat enigmatic carboxyl terminus
separately bind ERα and ERβ, and in doing so, augments the ERs function. In vitro studies
have shown that AKAP13 also binds the retinoid x receptor (RXR) (Segars, 1993), the
peroxisome proliferator-activated receptor (PPAR), and the thyroid hormone receptor
(Rubino, 1998).
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Figure 1.4| AKAP13 involved in PKA signaling pathway. Ligand binding of G-protein
coupled receptors (GPCRs) stimulates the Gα subunit thereby increasing production of
cAMP via Adenylyl Cyclase (AC). cAMP binds to PKA releasing the catalytic (C)
subunits which phosphorylate downstream effectors such as cAMP response element
binding protein (CREB). AKAP13 is shown tethered to PKA; AKAP13 localizes to
discrete subcellular micro-domains thereby focusing the generic signaling molecules to
specific downstream targets (Kirschner, 2009).

28
Due to AKAP13’s interaction with NHRs, it should come as no surprise that
AKAP13 is found to be highly expressed in reproductive and immune tissues.
Additionally, AKAP13 is found to be highly expressed in the heart, skeletal muscle,
hematopoietic cells, pancreas, and lungs (Rubino, 1998). Given AKAP13’s diverse tissue
expression and role as a pathway rectifier, one can hypothesize that AKAP13’s role in each
of the tissues is not identical. In fact, AKAP13 can bring common second messengers and
widely used signaling cascades to a focused endpoint depending on the needs of the cell
(Welch, 2010) (Scott, 2010).
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AKAP13 isoforms
The AKAP13 gene is alternatively spliced and encodes several splice variants. Of
these, three mRNA transcripts have been well characterized: 5.3kb, 8.5kb, and 10.0kb.
These AKAP13 transcripts, and subsequent proteins are not ubiquitous in human body
tissues. The proteins’ roles vary depending on the tissue of expression, and the cellular
context. Some transcripts are found highly expressed in some tissues while having less
expression in other tissues (Toksoz and Willams, 1994) (Uhlen, 2015) (Fig. 1.5a-c).
The 5.3kb transcript encodes a 170kDa protein (Brx) and is highly expressed in
human breast and reproductive tissue. Northern blot data has also shown this isoform to be
present in human heart muscle, breast cancer, and reproductive tissues (Rubino 1998). The
expression pattern of Lbc, as described in 1994 by Toksoz and Williams, is similar to, but
not exactly like AKAP13’s. Notably, the cDNA called Lbc was found to be a fusion of 2
products encoded by two different genes. AKAP13 is present in the tissues that Lbc is
present, but is also present in tissues where Lbc is not, such as breast and reproductive
tissue. Brx has a predicted nuclear localization signal (NLS) and can be found in both the
nucleus and cytoplasm, with the latter being the more common location (Rubino 1998).
The 8.5kb transcript encodes a ~220kDa protein and is expressed in the following
tissues: spleen, thymus, ovary, peripheral leukocytes, pancreas, skeletal muscle, lung,
placenta, and heart muscle (Rubino, 1998). This AKAP13 isotype is found in the
cytoplasm. Less is known about this particular isoform since most research has focused on
other splice variants.
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The 10.0kB transcript is translated into the ~310 kDa AKAP13 protein; this splice
variant is found to be highly expressed in heart tissue and binds actin and myosin filaments
in the cytoplasmic compartment of the cell. Further characterization of this isoform
showed that AKAP13 was required for murine heart development (Mayers, 2010). In the
absence of AKAP13, mice homozygous for the AKAP13 null allele died by embryonic day
10.5-11.0 (Mayers, 2010). This transcript is also found highly expressed in the following
tissues: placenta, lung, skeletal muscle, pancreas, and ovary. Details for the role of
AKAP13 in the heart will be discussed in Chapter 2.
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Figure 1.5| AKAP13 protein and transcript distribution in humans.
a) Schematic showing full length AKAP13 RNA (left of organ icon) and
protein (right of organ icon) expression in selected organs and tissues.
Colored bars represent individual tissues. From top to bottom they are as
follows: Brain (dark green), Endocrine tissues (dark purple), Bone marrow
and immune system (grey), Muscle tissues (red), Lung (yellow), Liver and
gallbladder (violet), Pancreas (green), Gastrointestinal tract (dark blue),
kidney and urinary bladder (orange), male tissues (light blue), female
tissues (pink), adipose and soft tissue (light green), skin (tan).
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Figure 1.5 cont.| AKAP13 protein and transcript distribution in
humans. b) Full length AKAP13 protein levels scored from no expression
to High protein levels throughout various organs and tissues. Colors are as
in a). c) RNA expression levels scored from low to high expression, colors
as in a) Fragments per Kilobase of transcript per Million mapped reads
(FPKM) throughout various organs and tissues (Uhlen, 2015) (Uhlen,
2010).
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CHAPTER 2: Results

Introduction
Like many complex diseases, heart disease can vary in presentation, severity, and
even outcome contingent upon the sex of the individual. Females commonly present to the
clinic later and with atypical symptoms and differences exhibited upon initial cardiac
examination, such as with electrocardiogram (ECG) (Curtis et al., 2012; Meyer et al.,
2014). Because of this, a better understanding of the mechanism and progression of heart
disease is of utmost importance in women’s health and sexual disparity research; failure to
do so has broad and far reaching health and economic implications (Fig. S.1) (Heron,
2009) (Pilote , 2007) (Heidenreich, 2011).
Heart disease is a complex, heterogeneous disease with many additional factors
indicated in its development including a complex hormonal milieu, and environmental
influences, such as diet and alcohol use. Furthermore, many studies have demonstrated
gender differences in the expression and types of cardiovascular disease, such as dilated
cardiomyopathy (DCM), a major underlying cause of heart failure (Frazao, 1999) (Pilote,
2007) (Konhilas, 2007) (Hershberger, 2010) (Wilson, 2007), stress cardiomyopathy
(Virani, 2007), and others. Nevertheless, reports have shown up to 50% of cardiomyopathy
cases can be considered idiopathic since the causative agent is unknown (Hershberger,
2010) (Hazebroek, 2012). The underlying complexity and pathway integration involved in
cardiomyocyte signaling, both inter- and intracellularly makes pathway analyses difficult
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at best (Wheeler-Jones, 2005) (Feliciello, 2001). While certain pathway components, such
as RhoA, PKA, CREB, and intracellular Ca2+ dynamics are understood to be important
factors in cardiac function and signaling, sarcomere formation, and cell differentiation, all
pieces of the signaling puzzle have yet to be identified (Diviani D, 2001) (Teramoto, 2003)
(Sahai, 1998) (Mauban, 2009) (Mayers, 2010) (Greenstein, 2011). It is likely that common
signaling pathways are engaged by multiple entities (Wheeler-Jones, 2005) (Feliciello,
2001) (Mayers, 2010). Therefore, key to understanding heart pathologies such as DCM,
especially as they are related to sex differences, lies in the elucidation of common genetic,
hormonal, or pathway defects. This common defect may involve permutations or
dysfunction in A Kinase Anchoring Protein (AKAP) 13.
AKAP13 is a nuclear hormone receptor modulator, dynamic scaffolding protein,
and pathway integration center with a conserved PKA-binding domain and Rho-GEF
activity (Rubino, 1998) (Mayers, 2010). AKAP13 not only possesses additional
functionality that surpasses any other known AKAP, but is of unique importance to the
medical and research communities due to its central and regulatory roles in familial breast
cancer, uterine fibroid development, immune response, and heart development (Rubino,
1998) (Mayers, 2010) (Rogers, 2008). In the heart disease literature, AKAP13 was
implicated as a major component of the PKD signaling pathway involved in cardiac
hypertrophy (Carnegie, 2008) (Taglieri, 2014). Notably, AKAP13 was up-regulated in
hypertrophic cardiomyocytes and was found to have important roles in activation and
localization of proteins involved in myocyte enhancer factor (MEF), specifically MEF2
signaling and transcriptional reprogramming (Carnegie, 2008). Previously our group
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showed that AKAP13 was essential for cardiac development and proper cardiomyocyte
differentiation. Global loss of Akap13 caused embryonic lethality by E10.5 to 11.0.
Embryos exhibited DCM with pericardial effusion, trabecular defects, and dysregulation of
key cardiac developmental genes such as Mef2 and Srf. Cardiac ultrastructural changes
showed defective cardiac sarcomere formation (Mayers, 2010) (Mauban, 2009). Similarly,
CREB deletion mutants produced dilated cardiomyopathy, mitochondrial dysfunction, and
increased female morbidity (Watson, 2010). This is particularly interesting since AKAP13
is known to modulate CREB (Baig, 2017, In Preparation).
Briefly, the AKAP13 gene is an alternatively spliced proto-oncogene located on
human chromosome 15q25.3 and on murine chromosome 7D2. AKAPs rectify cAMP
signaling pathways by tethering cAMP-dependent Protein Kinase A (PKA) to subcellular
micro-domains, such as organelles and other membranes (Welch, 2010). Within these subcellular niches, AKAPs act as engaged scaffolding proteins or signaling centers, holding
PKA, or other signaling enzymes, closer to substrates, downstream signaling enzymes, and
other relevant, supplemental molecules and co-factors. AKAP13 (also known as Brx and
AKAP-Lbc), was first isolated by Segars et al., from estrogen-responsive breast cancer
cells (Segars, 1993). Further studies by our group showed that the majority of AKAP13
isoforms modulated estrogen receptors and other nuclear hormone receptors through a
conserved carboxyl-terminal LXXLL nuclear receptor-interacting domain (NRID)
ultimately affecting the transcriptional program (Rubino, 1998) (Kino, 2006). Both the Nterminal and carboxyl-terminal conserved domains have key regulatory functions.

36
The protein kinase A (PKA) anchoring motif, whereby AKAP13 was classified, is
encoded in the N-terminal region. Interestingly, not all isoforms of the protein include this
PKA domain (e.g. 170kDa Brx) (Rubino, 1998). Furthermore, AKAP13 was found to be
the only known AKAP with Guanine Nucleotide Exchange Factor (GEF) activity via
conserved DH and PH domains (Mayers, 2010). Homodimerization of AKAP13 carboxyl
domains have been reported to regulate Rho-GEF activity (Baisamy, 2005). Rho GTPases
have been reported to have an important role in sarcomere development in cardiomyocytes.
They have also been shown to affect the cell cytoskeleton (Sah, 1999) (Majumdar, 1999)
(Kawamura, 2003). Additionally, RhoA, a known target of AKAP13, has been reported to
influence downstream components including GATA-4 and Serum Response Factor (SRF)
(Park, 2002). GATA-4 and SRF are known to be essential for cardiomyocyte
differentiation.
For proper Srf gene transcription and actin filament organization to take place, Rho
GTPase signaling pathways must be intact and fully functioning (Park, 2002) (Diviani,
2001) (Teramoto, 2003) (Sahai, 1998). Since AKAP13 has been reported to bind and
activate RhoA (and other Rho family GTPases such as RhoB and RhoC) via the GEF
domain, it is therefore likely that AKAP13 also influences cardiomyocyte differentiation,
and may be equally important to previously mentioned factors (Wei, 1998) (Sterpetti,
1999) (Diviani, 2001) (Charron, 2001) (Carnegie, 2008) (Teramoto, 2003) (Sahai, 1998).
Principally, AKAP13 acts as a central pathway integrator for an array of signaling
pathways while also providing a means to add specificity and spatiotemporal fidelity to
various effectors both upstream and downstream. AKAP13 conveys upstream information
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by coordinating signals from cell membrane LPA receptors, thrombin, and osmoreceptors
via G-proteins (Diviani, 2001) (Kawamura, 2003) (Huang, 2005). Gα12 has been one of the
G proteins most focused on with regard to interaction with AKAP13. However, AKAP13
has been shown to mediate signaling by the following G-proteins: Gα13, Gα14, Gαq, and
Gα15 (Ruwhof, 2000) (Petroff, 2001) (Schmidt, 2002) (Wei, 1998). Additionally, data have
shown AKAP13 action downstream of ET-1, and α- and β- adrenergic receptors (Rubino,
1998) (Taglieri, 2014) (Carnegie, 2008).
Given the role of AKAP13 in cell signaling, its ability to modulate estrogen
receptors, transcription factors and PKA, demonstrated effects on SRF and MEF2c
expression levels, essential role in proper embryonic cardiac sarcomere development, and
its robust expression in the both the human (Fig. S.2a, b) and mouse (Fig. S.2c, d) adult
myocardium (Mayers, 2010), we hypothesized that a functional AKAP13 protein is
required for cardiomyocyte function in the adult heart; defective function of AKAP13
may induce ventricular dysfunction and cardiac sarcomeric disorganization.
Moreover, we postulated that the carboxyl region of AKAP13 plays a vital role in the
regulation and coupling of PKA and Rho-GEF activity in order to signal and modulate
downstream effectors specifically involved in cardiac signaling events. Resent reports have
shown an increasingly complex role for AKAP13 in both physiologic and
pathophysiologic states. Because of this, investigation of AKAP13’s role in the adult heart
will provide essential mechanistic insights, open new avenues for therapeutics, and
facilitate a better characterization of sex dependent differences in heart disease
presentation and progression.
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Establishment of conditional cardiac-specific Akap13 knockout mouse model
To better understand the physiologic role of Akap13 in adult cardiac function,
conditional knockout (Akap13cKO) mice were generated using a Cre-Lox deletion strategy
targeted to the guanine nucleotide exchange factor (GEF) domain of Akap13 (Fig. 2.1).
Sequencing analysis and polymerase chain reaction (PCR) were used to verify the desired
construct in vitro and correct recombination and presence of LoxP sites in vivo (Fig. S.3af). In vitro studies confirmed expected Cre-recombination (Fig. S.4a-c). An inducible,
tissue-specific Cre approach was used since global Akap13 knockout resulted in embryonic
lethality by embryonic day 10.5-11.0, as previously described by our group (Mayers,
2010). Moreover, the role of Akap13 in the adult mouse heart could be more precisely
studied with the use of an inducible, cardiac tissue-specific Cre-expressing model since
multi-organ system involvement and potential off-target effects would be reduced or
eliminated (Fig. S.5). The well described Cre-recombinase-expressing mouse model αMHC-MerCreMer (MCM), driven by the α-MHC promoter, was used to achieve cardiac
tissue specificity (Sohal, 2001). For generation of the conditional knockout model, adult
mice at three months of age with homozygous floxed Akap13 alleles and expressing αMHC-MerCreMer (Akap13cKO-MCM) were administered tamoxifen treatment via tamoxifenlaced chow (40mg/kg body weight) for four weeks for induction of Cre-mediated excision.
Mice were induced at three months of age for comparison with published data (Sohal,
2001). Assays were performed at least 3 weeks following treatment cessation.
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Figure 2.1| Cre-lox deletion strategy for murine A Kinase Anchoring Protein 13
(Akap13) gene. Shown are the Wild Type (WT), Akap13Flox, and Akap13cKO alleles. A
Cre-lox deletion strategy was used to target the guanine nucleotide exchange factor (GEF)
region with flanking Dbl-homology (DH) and pleckstrin homology (PH) conserved
domains targeted for deletion. Flippase (FLP) recombinase-recombination target (FRT)
site remained from removal of the FRT flanked neomycin cassette. Solid arrows (black and
red) indicate binding sites for selected PCR primers used for genotyping analyses.
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To control for possible treatment effects, a second inducible, cardiac-specific Creexpressing mouse model was included in the study: Tnnt2-rtTA; TetO-Cre (TOC). The
doubly transgenic Tnnt2-rtTA promoter was the cardiac specific driver for TOC as
described in the literature (Wu, 2010). For generation of the second conditional knockout
model, adult mice at three months of age with homozygous floxed Akap13 alleles and
expressing

Tnnt2-rtTA;TetO-Cre

(Akap13cKO-TOC)

were

administered

doxycycline

(1mg/mL) via their water source for one to two weeks for induction of Cre-mediated
excision. Assays were performed at least 1 week following treatment cessation.
The efficiency of Akap13 knockdown was monitored through real-time quantitative
polymerase chain reaction (RT-qPCR) (Fig. 2.2), in situ hybridization (ISH) (Fig. 2.3),
immunohistochemistry (IHC) (Fig. 2.4), Western (Fig. 2.5) and Southern blotting (Fig.
S.6). Similar outcomes were observed between the two Cre models (MCM and TOC) with
comparable gene knockdown. Therefore, both Cre models utilized were efficient and
achieved Akap13 knockdown with tissue specificity, and will hereafter be referred to as
Akap13cKO-MCM or Akap13cKO-TOC where appropriate. Where Akap13cKO is used, combined
results were analyzed or overall conclusions were made for both models. Genotyping was
performed via PCR using gDNA isolated from the tail (Fig. S.7). For analytical purposes,
background strain was considered, and the two different Cre models were analyzed with
their appropriate background except where noted (for combined knockout analyses). For
controls, littermates were used where possible, and either expressed the desired Cre and
were not given treatment or did not express the Cre and were given treatment. No
statistical differences were found between the two (Tables ST.1-ST.3) and will henceforth
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be referred to as control mice. In all cases, results for Akap13cKO-MCM mice will be given in
the text. References to Akap13cKO-TOC mice will be noted where appropriate. Please note
that the Akap13cKO-TOC was introduced later in the project, so were not available for every
assay. Additional Akap13cKO-TOCdata is located in Appendix B.
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Figure 2.2| RT-qPCR analyses showed knockdown of Akap13. Here we show
qRT-PCR analysis of AKAP13 expression represented as mRNA fold change
comparison between control mice (F/F, MCM-; Tamoxifen diet) (n=5) and
Akap13cKO-MCM mice (n=5). Akap13 expression in cKO mice was lower than
Akap13 expression in control mice (p<0.001) which demonstrated appropriate gene
knockdown. Each biological replicate (single mouse sample) had three technical
replicates; results were normalized to GAPDH and 18S housekeeping genes. Three
independent experiments were performed to validate results shown; error reported
as S.E.M. Student’s t-test was performed for statistical analysis.
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Figure 2.3| In situ Hybridization (ISH) with riboprobe showed reduction of
Akap13 transcripts. Here we demonstrated efficient knockdown of Akap13 using
In Situ Hybridization (ISH) with a riboprobe. The panels on the left (40X) show a)
control (n=4) and c) Akap13cKO (n=4) in 5 month old adult murine hearts. The
panels to the right (100X) are magnifications of the boxed regions b) control and d)
Akap13cKO, and substantiated the absence of Akap13 mRNA in the Akap13cKO-MCM
mouse hearts.
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Figure 2.4| Immunohistochemistry showed reduction in AKAP13 protein levels in
Akap13cKO-MCM mouse hearts. a) Immunohistochemistry (IHC) showed positive antiAKAP13 staining (pinkish-red) in Control mouse hearts (n=3) b) IHC showed reduced
anti-AKAP13 staining in the Akap13cKO-MCM mouse hearts (n=3). c) Enlargement of a)
showed a striated pattern in adult control mouse hearts (red arrows). d) Enlargement of b)
showed faint and disrupted AKAP13 protein distribution (white arrow) which indicated
knockdown was achieved. Scale bar shown is 50µm.
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Figure 2.5| Quantification of Western Blot showed reduced AKAP13 protein
levels. Western blot verified AKAP13 protein knockdown in Akap13cKO-MCM
cardiomyocytes. Notably, multiple cell types comprise cardiac tissue. Both Cre
models were driven by cardiomyocyte specific promoters, therefore Akap13 was
expressed in fibroblasts which account for more than 50% of cardiac cells. For
statistical analysis, Student’s t-test was used for comparison between control (F/F,
MCM-; Tamoxifen diet) (n=3) and Akap13cKO-MCM mice (n=3) (where * indicates
significant value p<0.05).
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Histology revealed dilated ventricular chambers and dysmorphic cardiomyocytes
Histologic examination of formalin fixed hematoxylin and eosin (H&E) stained
Akap13cKO-MCM mouse heart tissue cross-sections at the level of the papillary muscles
revealed dilated left ventricles in Akap13cKO mice (n=4) compared to controls (n=3)
(Akap13cKO: 196.62cm2 ± 19.10; control: 127.5cm2 ± 5.76; p<0.05) (Fig. 2.6). Strikingly,
areas of less intense eosin staining were observed along with a more granular, disorganized
appearance of most of the cardiomyocytes, which also demonstrated pyknotic nuclei, in
Akap13cKO-MCM cardiac tissue sections compared to controls which suggested cytoskeletal
and potentially organellar changes (Fig. 2.7). In situ hybridization with a riboprobe was
performed to assess AKAP13 transcript levels in the heart tissue. Areas of more intense
and less intense staining were seen. Areas of more intense staining were likely to
correspond with normal appearing cardiomyocytes, and areas with less intense, or no
staining were likely to correspond with the dysmorphic and likely necrotic cardiomyocytes
secondary to the loss of Akap13 (Fig. 2.8). There were no inflammatory cells or other signs
of infection, either acute or chronic in nature. Since many disrupted cardiomyocytes were
observed in the Akap13cKO-MCM hearts, terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) was performed to assess apoptosis by fluorescently labeling
fragmented DNA. However, apoptosis was not found to be increased in the Akap13cKO-MCM
cardiac tissue compared to control tissue (Fig S.8). Since apoptosis was not indicated,
other mechanisms of cell death, such as autophagy, remain plausible.
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Figure 2.6| Knockdown of Akap13 induces ventricular dilation in the adult murine
heart. a,b) (10X) Here we showed haematoxylin/eosin (H&E) stained mid-ventricular
cross-sections of murine hearts at the level of the papillary muscles. Controls (F/F, MCM-;
Tamoxifen diet) (n=3) and Akap13cKO mice (n=4). The Akap13cKO hearts had a visibly
enlarged left ventricular chamber. The cKO shown here is from an Akap13cKO-TOC mouse,
but is representative of both the Akap13cKO-TOC and Akap13cKO-MCM mice.
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Figure 2.6 cont.| Knockdown of Akap13 induces ventricular dilation in the
adult murine heart. c) Quantification of the ventricles of Akap13cKO hearts
compared to controls (F/F, MCM-; Tamoxifen diet) showed enlarged left
ventricular chambers in the Akap13cKO hearts compared to the controls (p<0.05).
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Figure 2.7| H&E stained Akap13cKO-MCM mouse cardiac tissue sections showed
disrupted cardiomyocytes. a,b) H&E stained cardiac tissue sections (40X) showed
disrupted cardiomyocytes with granular and irregular appearing eosinophilic cytoplasmic
staining and pyknotic nuclei indicative of necrosis. The white arrows show normal, healthy
cardiomyocytes (control-left panel) whereas the red arrows show the dysmorphic
cardiomyocytes (Akap13cKO-MCM -right panel). c) Enlargement of b) revealed the majority
of cardiomyocytes in the Akap13cKO-MCM were disrupted (red arrows).
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Figure 2.8| In situ hybridization (ISH) showed reduced Akap13 message in
Akap13cKO-TOC mouse hearts. a,b) In situ Hybridization (ISH) with an Akap13 riboprobe
(bluish-purple) showed marked reduction of Akap13 transcripts in the Akap13cKO-TOC
mouse hearts (b) compared to Akap13Het-TOC mouse hearts (a). Persisting Akap13
expression likely occurred in cardiac fibroblasts or a small subset of cardiomyocytes (20%)
where recombination did not occur.
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Electron Micrographic analyses showed disrupted sarcomeres and mitochondria
Given the significant histologic changes observed in the Akap13cKO mice, we next
sought to characterize the cardiac sarcomeres and ultrastructural underpinnings of the
Akap13cKO cardiac tissue compared to controls. Immunohistochemistry with antisarcomeric alpha-actinin revealed disruption of the cardiac sarcomere. Normal sarcomeric
banding patterns were seen in control mice (n=3), but not in Akap13cKO mice (Fig. 2.9a).
Scrutiny of electron micrographic data revealed widespread sarcomeric disorganization in
the Akap13cKO mice (n=7) compared to controls (n=6) (Fig. 2.9b). Normal sarcomere
banding patterns were observed in the controls. The majority of the tissue examined in
Akap13cKO mice was in complete disarray with severely disrupted sarcomeres, including
missing and blind-ended z-discs and abnormal or missing bands (e.g. A-band). Some areas
were so severely affected that it was difficult to ascertain the existence of sarcomeres
altogether (Fig. S.9). Moreover, mitochondria showed significant pathological changes in
Akap13cKO mice compared to controls. Mitochondria were increased in number, were
swollen or of differing sizes, and partially or completely lacked cristae (Fig. 2.10-2.12).
Additional observations included increased lipid droplets, inclusions, and lamellar bodies
in the Akap13cKO-MCM mice (Fig. S.10).
In sum, these data indicated widespread sarcomeric and severe mitochondrial
disruption in Akap13cKO mice. Of note, mitochondria in Akap13cKO mouse cardiac tissue
were lacking some or all of their cristae, appeared to have increased fusion/fission, and
many were swollen and missing their outer mitochondrial membranes. Cardiac sarcomeres
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were disorganized and missing some or all of the necessary bands to form an adequate
contractile unit. While some electron micrographic sections from the Akap13cKO mice had
more normal appearing ultrastructure, most of the observed sections had widespread
pathological disorganization.
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Figure 2.9| IHC showed disrupted sarcomeric alpha actinin in Akap13cKO mouse
cardiac tissue sections. a) Control cardiac tissue sections showed normal staining with
anti-sarcomeric alpha actinin (20X). b) Enlargement of a) showed regular, striated
sarcomeric banding pattern in the control mouse cardiac tissue.
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Figure 2.9 cont.| IHC showed disrupted sarcomeric alpha actinin in Akap13cKO mouse
cardiac tissue sections. c) Akap13cKO mouse cardiac tissue sections showed disrupted and
irregular sarcomeric banding patterns (20X). d) Enlargement of c) highlighted the
sarcomeric pathology seen in Akap13cKO mouse cardiac tissue sections.
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Figure 2.10| Electron Microscopy revealed significant changes to the cardiac
sarcomeres in Akap13cKO mouse cardiac tissue. a) Electron micrograph, Control mouse
cardiac tissue (15,000x) showed normal sarcomeric banding patterns. Mitochondria were
uniform and aligned along the sarcomeres, as expected. b) Electron micrograph,
Akap13cKO mouse cardiac tissue showed significant disruption of the sarcomeres including
loss of the normal banding pattern (e.g. A-band).
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Figure 2.11| Electron Microscopy showed ultrastructural disarray in Akap13cKO mouse
cardiac tissue. a) Electron micrograph, Control mouse cardiac tissue showed typical
sarcomeric banding pattern and typical group of mitochondria. b) Electron micrograph,
Akap13cKO mouse cardiac tissue showed significant disarray with blind ending sarcomeres,
and mitochondria lacking cristae.
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Figure 2.12| Electron Microscopy showed mitochondria lacking cristae and lamellar
inclusions. Electron micrograph, Akap13cKO mouse cardiac tissue showed an increased
number of mitochondria. Mitochondria were either partially or fully lacking cristae. Some
cristae were present (white arrow), but most areas were lacking cristae (red arrow).
Lamellar inclusions (yellow arrow) were likely cristae extruded from the mitochondria.
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Akap13cKO mice developed dilated cardiomyopathy
Magnetic Resonance Imaging (MRI) is considered the gold standard for evaluating
cardiac volume due to its ability to quantify a three-dimensional dataset, unlike other
imaging modalities. We performed MRI to evaluate the cardiac volumes and function of
Akap13cKO-MCM and Akap13cKO-TOC mice (collectively referred to as Akap13cKO). Heart rate,
body temperature, and respiration rates were monitored for each animal during the
procedure. Results for Akap13cKO-TOC mice were not statistically different than Akap13cKOMCM

mice (data not shown). Akap13cKO-MCM mice were imaged in two different time ranges:

<8 weeks post-cessation of treatment for Cre-mediated excision (hereafter <8 weeks postrecombination) or ≥8 weeks post-cessation of treatment for Cre-mediated excision
(hereafter ≥8 weeks post-recombination).
Left ventricular ejection fraction (LVEF) is the mainstay for assessment of cardiac
function and can be calculated from End Diastolic Volume (EDV) and End Systolic
Volume as shown in the following equation:

Akap13cKO-MCM mice exhibited decreased resting (baseline) LVEF (50.1% ± 2.5) compared
to controls (63.75% ± 1.64; p<0.01) characteristic of dilated cardiomyopathy (Fig. 2.13-
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Fig. 2.14a). Mice were then analyzed based on their time post-recombination. Akap13cKOMCM

mice in the <8-week post-recombination group exhibited lower LVEF at baseline

(51.64% ± 3.89) compared to controls (68.01% ± 2.65; p<0.00001) (Fig. 2.14b) as did the
Akap13cKO-MCM mice in the ≥ 8-weeks post-recombination group (53.56% ± 4.05)
compared to controls (65.58% ± 3.16; p<0.01) (Fig. 2.14c).
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Figure 2.13| Akap13cKO-MCM mice exhibited dilated left ventricles by magnetic
resonance imaging (MRI). a) MRI with contrast (0.2-0.3 mmol/kg Magnevist),
short axis (SAX) slice at the level of the papillary muscles. Control mice (n=9)
displayed typical left ventricle (LV) and right ventricle (RV) morphology. Inset
shows the enlargement of the boxed region which highlighted the circular shape of
the LV. b) MRI with contrast (0.2-0.3 mmol/kg Magnevist), short axis (SAX) slice
at the level of the papillary muscles. Akap13cKO-MCM mice (n=7) showed dilated left
ventricles. Inset shows the enlargement of the boxed region which highlighted the
elliptical shape of the LV. Student’s t-test used for statistical analyses.
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Figure 2.14| Akap13cKO-MCM mice exhibited significantly decreased left ventricular
ejection fraction (LVEF). a) MRI with contrast (0.2-0.3 mmol/kg Magnevist), Normal
left ventricular ejection fraction (LVEF) is 55-70%. Overall, Akap13cKO-MCM mice (n=14)
had reduced LVEF compared to control mice (n=15) (p<0.001). b) MRI with contrast (0.20.3 mmol/kg Magnevist), Akap13cKO-MCM mice in the < 8 weeks post-recombination group
had significantly lower LVEF compared to controls (p<0.001). c) MRI with contrast (0.20.3 mmol/kg Magnevist), Akap13cKO-MCM mice in the ≥ 8 weeks post-recombination group
had significantly lower LVEF compared to controls (p<0.0001). Student’s t-test used for
statistical analyses.
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Furthermore, Akap13cKO-MCM mice exhibited an increased left ventricular end
diastolic volume index (EDVI) (2.55µL/g ± 0.49) compared to control mice (2.02 µL/g ±
0.21; p<0.001), and an increased left ventricular end-systolic volume index (ESVI) (1.21
µL/g ± 0.29) compared to controls (0.67µL/g ± 0.11; p<0.00001) (Fig. 2.15a). Akap13cKOMCM

mice also showed increased left ventricular end diastolic mass index (EDMI) values

(4.1 mg/g body weight ± 4.4E-4) and end systolic mass index (ESMI) values (4.4 mg/g
body weight ± 0.4.8E-4) compared to controls (EDMI: 3.4 mg/g body weight ± 4.4E-4;
p<0.01) (ESMI: 3.5 mg/g body weight ± 3.1E-4; p<0.00001) (Fig. 2.15b). Taken together,
these data indicated dilation and hypertrophy of the left ventricle with impaired
contractility in Akap13cKO-MCM mice.
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Figure 2.15| Akap13cKO-MCM mice had significantly increased volume and mass indices.
a) MRI with contrast (0.2-0.3 mmol/kg Magnevist), Overall, Akap13cKO-MCM mice had an
increased end diastolic volume index (EDVI) (p<0.0001) and end systolic volume index
(ESVI) (p<0.001) compared to controls. Student’s t-test used for statistical analyses. b)
MRI with contrast (0.2-0.3 mmol/kg Magnevist), Overall, Akap13cKO-MCM mice had an
increased end diastolic mass index (p<0.001) and end systolic mass index (ESMI)
(p<0.0001). Student’s t-test used for statistical analyses.
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When stratified based on time post-cessation of treatment for Cre-mediated
excision, Akap13cKO-MCM mice in the <8 weeks post-recombination group exhibited
increased left ventricular EDVI (2.65µL/g ± 0.31) (control: 2.03µL/g ± 0.20; p<0.0001)
and ESVI (1.29µL/g ±0.23) (control: 0.65µL/g ± 0.094; p<0.00001). EDMI was also
increased compared to control (3.9 mg/g body weight ± 0.00035) (control: 3.12 mg/g body
weight ± 0.00037; p<0.005) as was ESMI (4.3 mg/g body weight ± 3.4E-4; control: 3.4
mg/g body weight a 2.7E-4; p<0.00001) (Table 2.1). Akap13cKO-MCM mice in the ≥ 8-weeks
post-recombination group had increased EDVI (Akap13cKO-MCM: 2.53 ± 0.45; control: 2.02
± 0.21) (p<0.01) and EDMI (Akap13cKO-MCM: 0.0044 ± 0.0003; control: 0.0038 ± 0.0002)
(p<0.01), but not ESVI or ESMI (p>0.05) (Table 2.2).
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Table 2.1| Resting MRI summary table for < 8 weeks post-recombination group.
Summary of data showing significant values for all MRI variables measured.
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Table 2.2| Resting MRI summary table for ≥ 8 weeks post-recombination group.
Summary of data showing significant values for all MRI variables measured.
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These data suggested dilation and hypertrophy in both the <8 weeks post-treatment
and the ≥8 weeks post treatment Akap13cKO-MCM mice. When the Akap13cKO-MCM mice were
compared to each other based on time post-treatment, the ≥8 weeks post-treatment group
had increased EDMI compared to the group <8 weeks post-treatment group (p<0.05).
Therefore, Akap13cKO-MCM mice exhibited left ventricular remodeling which resulted in
compensatory hypertrophy concomitant with time post- Akap13 excision.
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Female Akap13cKO mice exhibited more severe DCM than male Akap13cKO-MCM mice
When stratified based on sex, both male (Fig. 2.16a) and female (Fig. 2.16b)
Akap13cKO-MCM mice had decreased LVEF at rest (male: 55.5% ± 4.46, female: 50.99% ±
3.80) compared to their respective controls (male: 68.5% ± 2.22; female: 66.25% ± 2.72;
all p<0.01). However, when female Akap13cKO-MCM mice were compared to male
Akap13cKO-MCM mice, females had lower LVEF than Akap13cKO-MCM male mice (p<0.05,
one-way). This was striking since reports in humans have shown that women have higher
LVEF than men (Chung, 2006). Similarly, Akap13cKO-TOC female mice exhibited decreased
LVEF (59.55% ± 3.49) at rest compared to female controls (69.8 ± 5.24; p<0.05).
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Figure 2.16| Male and female Akap13cKO-MCM mice showed significantly reduced
LVEF. a) MRI with contrast (0.2-0.3 mmol/kg Magnevist), Male Akap13cKO-MCM mice
(n=7) had significantly reduced LVEF compared to control mice (n=4) (p<0.001). b) MRI
with contrast (0.2-0.3 mmol/kg Magnevist), Female Akap13cKO-MCM mice (n=7) showed
significantly reduced LVEF compared to control mice (n=6) (p<0.001). Student’s t-test
was used for statistical analyses. Student’s t-test used for statistical analyses.
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When the male and female mice were stratified based on time post-recombination,
male Akap13cKO-MCM mice in the <8 weeks post-recombination group also exhibited
reduced LVEF at rest (53.32% ± 3.67) compared to controls (baseline: 68.82% ± 2.21;
p<0.001). However, male Akap13cKO mice ≥ 8 weeks post-recombination exhibited only a
reduced LVEF trend at baseline (58.41% ± 3.69) compared to controls (64.33% ± 2.45;
p>0.05). On the other hand, female Akap13cKO-MCM mice at both time points showed
statistically significant reduction in LVEF at rest (<8 weeks: 47.86 ± 4.50; ≥8 weeks:
52.95% ± 2.94) compared to respective controls at rest (<8 weeks: 66.48 ± 4.37; ≥8 weeks:
69.89% ± 3.62) (<8 weeks p=0.0025; ≥8 weeks p<0.01).
Furthermore, male and female Akap13cKO-MCM mice had increased left ventricular
EDVI (male: 2.38µL/g ± 0.36; female: 2.72µL/g ± 0.38 ) and ESVI (male: 1.07 ± 0.26;
female: 2.72 ± 0.38) compared to controls (EDVI: male: 1.84µL/g ± 0.21; female:
2.19µL/g ± 0.14) (ESVI: male: 0.585 ± 0.098; female: 0.74 ± 0.087) (EDVI: male: p<0.05;
female: p<0.05) (ESVI: male: p<0.05; female: p< 0.001). Male and female Akap13cKO-MCM
mice also had increased left ventricular EDMI (male: 3.84µL/g ± 3.9E-4; female: 4.4µL/g
± 3E-4) compared to controls (male: 3.2 µL/g ± 4E-4; female: 3.3 µL/g ± 4E-4) (male:
p<0.05; female: p<0.001) and increased ESMI (male: 4.1 ± 0.00014; female: 4.7 ±
0.00016) compared to controls (male: 3.3 ± 0.00014; female: 3.6 ± 0.00012) (male:
p<0.01; female: p<0.001). It is well established in the literature that females typically have
lower EDMI than males. However, female Akap13cKO-MCM mice had increased EDMI
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compared to male Akap13cKO-MCM mice (p<0.05). This suggested that female Akap13cKOMCM

mice had increased ventricular remodeling compared to males (Table 2.3).
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Table 2.3| Resting MRI summary table stratified by sex. a) Summary of male data
showing significant values for all MRI variables measured. b) Summary of female data
showing significant values for all MRI variables measured.
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When the <8 weeks and ≥8 weeks groups were stratified based on sex, males in the
<8 weeks post-recombination group demonstrated increased EDVI (2.5 ± 0.337) (control:
1.92 ± 0.21) (p=0.27) and ESVI (1.18 ± .24) (control: 0.62 ± 0.093) (p<0.01). EDMI
values were modestly increased (p>0.05) (supplemental), but ESMI was increased (4.2
mg/g body weight ± 2.6E-4) (control: 3.3 ± 3.2E-4) (p<0.01). At ≥8 weeks postrecombination, male Akap13cKO-MCM mice only showed modest increases in EDVI, ESVI,
EDMI and ESMI (supplemental) (all p>0.05). Moreover, female Akap13cKO-MCM mice at <8
weeks post-recombination showed increased EDVI (2.84 ± 0.09) (control: 2.16 ± 0.09)
(p<0.001), and ESVI (1.44 ± 0.12) (control: 0.71 ± 0.051) (p<0.001). EDMI was also
increased (4.24 mg/g body weight ± 1.6E-4) (control: 3.1 mg/g body weight ± 2.3E-4)
(p<0.01) as was ESMI (4.5 mg/g body weight ± 3.2E-4) (control: 3.44 ± 1.6E-4) (p<0.01).
Female Akap13cKO-MCM mice at ≥8 weeks post-recombination had modestly increased
EDVI (2.62 ± 0.48) (control: 2.13 ± 0.24) (p=0.11), but maintained an increased ESVI
(1.26 ± 0.30) (3.8 ± 2.9E-4) (p=0.029/0.059). Additionally, EDMI was increased (4.44 a
3.6) (control: 3.8 ± 2.8E-4) (p=0.059 one-way) as was ESMI (4.8 mg/ g body weight ±
4.6E-4) (control: 3.8 mg/g body weight ± 2.9E-4) (p<0.05).
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Female Akap13Het-MCM exhibited dilated cardiomyopathy
Mice haploinsufficient (n=11) for the conditional null allele (hereafter Akap13HetMCM

) had lower LVEF at baseline (59.66% ± 6.6) compared to controls (66.66% ± 3.88;

p<0.05). When Akap13Het-MCM mice were stratified based on sex, female Akap13Het-MCM
mice exhibited decreased LVEF compared to controls at rest (57.3% ± 7.78) (control:
65.87% ± 2.68) (p<0.05). However, no left ventricular phenotype was seen with male
Akap13Het-MCM mice (p>0.05) at rest (Fig. 2.17). These data showed that females were more
affected than males associated with Akap13 gene disruption, even in the haploinsufficient
state.

76

Figure 2.17| Male and female Akap13Het-MCM mice showed differences in LVEF. a) MRI
with contrast (0.2-0.3 mmol/kg Magnevist), Male Akap13Het-MCM mice (n=3) showed no
changes in LVEF compared to control mice (n=4) (p>0.05). b) MRI with contrast (0.2-0.3
mmol/kg Magnevist), Female Akap13Het-MCM mice (n=7) had significantly lower LVEF
compared to control mice (n=7) (p<0.05). Student’s t-test used for statistical analyses.
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Overall, Akap13Het-MCM mice demonstrated no significant changes to left ventricular
EDVI, ESVI, EDMI, or ESMI (Table ST.5) compared to controls (n=5), however, sexdependent changes were observed. Female Akap13Het-MCM mice demonstrated a modestly
increased left ventricular EDVI (2.52µL/g ± 0.43) (control: 2.22 ± 0.14; p=0.13), and
increased ESVI (1.1 µL/g ± 0.39) (control: 0.76 µL/g ± 0.09; p=0.057). Additionally,
female Akap13Het-MCM mice showed increased left ventricular EDMI (4.0 mg mass/g body
weight ± 7E-4) (control: 3.3 mg/g body weight ± 4E-4; p=0.057), and modestly increased
ESMI (4.0 mg/g body weight ± 6E-4) (control: 0.0036 ± 2.9E-4; p=0.15) (Table 2.4).
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Table 2.4| Resting MRI summary Akap13 haploinsufficient female. Female Akap13HetMCM
mice had significant differences in cardiac function whereas male Akap13Het-MCM mice
did not.
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Akap13cKO mice failed to increase LVEF with stress testing
After resting cardiac MRI, stress testing with dobutamine, a β1-adrenergic receptor
agonist, and positive inotropic agent, was conducted. Dobutamine was administered at a
low dose (10ug/kg/min; hereafter LVEF-10) and a high dose (40ug/kg/min; hereafter
LVEF-40) to assess cardiac response. LVEF should increase with inotropic stimulation
during stress. Akap13cKO-MCM mice failed to mount an appropriate response to the
dobutamine stress; LVEF for Akap13cKO-MCM mice was decreased (LVEF-10: 56.99%
±8.12; LVEF-40: 63.13% ± 10.31) compared to control LVEF (LVEF-10: 77.09% ± 5.89;
LVEF-40: 83.47% ± 4.17) at both the low (p<0.00001) and high doses (p<0.00001) of
dobutamine (Fig. 2.18).
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Figure 2.18| Akap13cKO-MCM mice exhibited decreased LVEF with dobutamine MRI
stress testing. a) Stress MRI with contrast (0.2-0.3 mmol/kg Magnevist), Akap13cKO-MCM
mice (n=13) had lower LVEF than control mice (n=15) with 10µg/kg/min dobutamine
MRI stress testing (p<0.001). b) Stress MRI with contrast (0.2-0.3 mmol/kg Magnevist),
Akap13cKO-MCM mice (n= 13) had lower LVEF than control mice (n=15) with 40µg/kg/min
dobutamine MRI stress testing (p<0.001). Student’s t-test used for statistical analyses.
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When stratified based on sex, both male and female Akap13cKO-MCM mice failed to
increase their LVEF with low dose dobutamine (male LVEF-10: 57.38% ± 8.98; female
LVEF-10: 56.65% ± 7.27) and high dose dobutamine (male LVEF-40: 61.53% ± 12.27;
female LVEF-40: 65.50% ± 8.03) compared to their respective controls [(male LVEF-10:
77.83% ± 5.76; female LVEF-10: 76.43% ± 5.91) and (male LVEF-40: 83.13% ± 4.29;
female LVEF-40: 83.76 ± 4.03)] (all p<0.01) (Fig. 2.19).
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Figure 2.19| Female and male Akap13cKO-MCM mice exhibited decreased LVEF with
dobutamine MRI stress testing. a,b) Stress MRI with contrast (0.2-0.3 mmol/kg
Magnevist), Male Akap13cKO-MCM mice had lower LVEF compared to control mice with
both 10µg/kg/min (p<0.001) and 40µg/kg/min Dobutamine stress MRI (p<0.001). c,d)
Stress MRI with contrast (0.2-0.3 mmol/kg Magnevist), Female Akap13cKO-MCM mice had
lower LVEF compared to control mice with both 10µg/kg/min (p<0.001) and 40µg/kg/min
Dobutamine stress MRI (p<0.001). Student’s t-test used for statistical analyses.
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Similarly, Akap13cKO-MCM mice in the <8 weeks post-recombination group failed to
increase their LVEF with stress testing (LVEF-10: 52.66% ± 8.21; LVEF-40: 59.68% ±
10.46) compared to controls (LVEF-10: 75.67% ± 4.32; LVEF-40: 82.79 ± 2.16; p<0.001,
both). Akap13cKO-MCM mice in the ≥8 weeks post-recombination group also failed to
increase their LVEF with stress testing (LVEF10: 62.04% ±4.09; LVEF40: 67.14% ± 8.45)
(p<0.01) compared to control mice at the same time point (LVEF10: 79.2% ± 7.15;
LVEF40: 84.49% ± 5.89).
When the <8 weeks post-recombination group and the ≥8 weeks postrecombination groups were stratified based on sex, male Akap13cKO-MCM < 8 weeks postrecombination showed statistically lower LVEF at both dobutamine dosages (LVEF-10:
54.92% ± 10.15; LVEF-40: 62.08% ± 13.31) compared to controls (LVEF-10: 78.00% ±
4.90; LVEF-40: 84.23% ± 1.31) (p<0.05, both). The ≥ 8 weeks post-recombination group
was able to respond at the lower dose of dobutamine (LVEF-10: 65.97% ± 5.20) (p=0.064
one-way), but failed to respond at the higher dose of dobutamine, with an actual drop in
LVEF to a lower level than their resting LVEF (LVEF-40: 56.80% ± 9.48) compared to
controls (LVEF-10: 77.46% ± 6.73; LVEF-40: 81.67% ± 6.08) (LVEF-40: p< 0.05).
However, female Akap13cKO-MCM showed decreased LVEF at both time points and both
dobutamine dosages (<8 weeks: LVEF-10: 49.65% ± 2.05; LVEF-40: 56.48% ± 1.07;
≥8weeks: LVEF-10: 60.62 ± 5.17; LVEF-40: 68.59 ± 4.69) compared to respective
controls (<8 weeks: LVEF-10: 73.72 ± 2.42; LVEF-40: 81.63 ± 2.01 ; ≥8 weeks: LVEF-
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10: 80.94 ± 7.14) ; LVEF-40: 87.31 ± 4.05) (<8 weeks: LVEF-10: p=1.61E-5 ; LVEF-40:
p=2.35E-6 ) (≥8 weeks: LVEF-10: p<0.05 ; LVEF-40: p<0.05).
Moreover, Akap13Het-MCM mice showed a lower LVEF trend with the lower dose of
dobutamine (LVEF 10: 65.33% ± 10.5) (p=0.05, one-way), but a significantly reduced
LVEF with the higher dose of dobutamine (LVEF40: 71.63% ± 8.97) (p<0.05 one way)
compared to controls (LVEF 10: 73.81% ± 3.68; LVEF 40: 80.25% ± 3.89), and thereby
demonstrated decompensation at the higher dobutamine dose. When Akap13Het-MCM mice
were stratified based on sex, female Akap13Het-MCM mice showed significantly reduced
LVEF at both dobutamine dosages (LVEF-10: 61.1% ± 10.42; LVEF-40: 68.01% ± 8.02)
(control: LVEF-10: 73.81% ± 3.68; LVEF-40: 80.85% ± 3.89) (LVEF-10 p<0.05; LVEF40: p<0.05). However, male Akap13Het-MCM mice showed no statistical changes with stress
testing (Table ST.6).
These data showed increased severity of cardiac phenotype in female Akap13cKOMCM

mice compared to male Akap13cKO-MCM mice, and a different cardiac response to stress

once the heart is compromised. Moreover, male mice could partially remodel over time,
but decompensated with stress. Females were less able to remodel with time and did not
show any inotropic response with stress. These data also showed that females were more
affected than males associated with Akap13 gene disruption, even in the haploinsufficient
state (Table 2.5).
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Table 2.5| Summary of resting left ventricular MRI values. Summary of resting left
ventricular MRI values stratified based on sex and time post-recombination. Akap13cKOMCM
mice exhibited dilated cardiomyopathy with compensatory hypertrophy. Females had
more significant MRI pathology than males.
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Akap13cKO mice developed right ventricular dilation and hypertrophy
The function of the right ventricle was assessed to determine any contribution to
the cardiac phenotype (Table 2.6). The right ventricular ejection fraction (RVEF) for
Akap13cKO-MCM mice was reduced (59.2% ± 3.93) compared to control mice (65.55% ±
5.03) (p<0.05). When stratified based on time post-recombination, Akap13cKO-MCM mice in
the <8 weeks post-recombination group showed the same pattern of right ventricular
dysfunction seen in overall genotype comparisons (60.07 ± 1.93) compared to controls
(68.45 ± 3.08; p=1.64E-5). Likewise, Akap13cKO-MCM mice in the ≥8 weeks group had
reduced RVEF (58.21 ± 5.20) compared to controls (65.37 ± 2.28) (p<0.05).
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Table 2.6| Summary of resting right ventricular MRI values. Summary of resting right
ventricular MRI values stratified based on sex and time post-recombination. Females have
more significant MRI pathology than males.
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Right ventricular assessment of male Akap13cKO-MCM mice compared to female
Akap13cKO-MCM mice demonstrated sex-dependent differences. Right ventricular ejection
fraction was reduced in both male Akap13cKO-MCM mice (59.42 ± 4.58) and female
Akap13cKO-MCM mice (58.97 ± 3.00) compared to control mice (male: 66.23 ± 2.72; p<0.05;
female: 68.19 ± 3.25; p<0.001). Male Akap13cKO-MCM mice in the <8 weeks postrecombination group showed reduced RVEF (60.24 ± 1.69) compared to respective
controls (66.82 ± 2.77) (p<0.01). However, male Akap13cKO-MCM mice in the ≥8 weeks
post-recombination group showed modestly reduced RVEF (58.05 ± 6.95) (63.96 ± 2.37)
(p>0.05). Conversely, female Akap13cKO-MCM mice in the < 8 weeks post-recombination
group exhibited markedly decreased RVEF (59.82 ± 2.26) compared to controls (69.76 ±
2.65; p<0.01). Moreover, female Akap13cKO-MCM mice in the ≥8 weeks post-recombination
group continued to exhibit significant reduction of RVEF (58.33 ± 3.32) compared to
respective controls (65.57 ± 2.31; p<0.05). These results suggested cardiomyopathy of the
right ventricle in Akap13cKO mice, with a more severe phenotype in female Akap13cKO mice
(Table ST.8a).
Right ventricular ejection fraction was also evaluated in Akap13Het-MCM mice and
was found to be decreased in Akap13Het-MCM mice compared to control mice (n=20)
(Akap13Het-MCM mice: 60.87% ± 1.83; Control: 65.23% ± 1.08) (p<0.05). Akap13Het-MCM
mice were also stratified based on sex.

Male Akap13Het-MCM mice showed decreased

RVEF (Akap13Het-MCM: 56.95% ± 3.58; Control: 63.30% ± 2.06) (p<0.05 one-way) (Table
ST.8b). Female Akap13Het-MCM mice exhibited significantly decreased RVEF (Akap13Het-
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MCM

: 63.11 ± 1.45; Control: 68.19 ± 1.15) (p<0.05) compared to controls (n=9) mirroring

the results of the Akap13cKO-MCM mice. These data suggested cardiomyopathy of the right
ventricle in Akap13Het-MCM mice.
Right ventricular volume indices were also evaluated. The EDVI of the right
ventricle was increased in Akap13cKO-MCM mice (1.78µL/g±0.36) compared to controls
(1.50µL/g ±0.30; p<0.05) as was the ESVI (0.72µL/g ± 0.17) compared to controls (0.48
µL/g ± 0.1; p<0.001). When stratified based on time post-recombination, Akap13cKO-MCM
mice in the <8 week post-recombination group showed the same pattern of right
ventricular dilation seen with overall genotype comparisons: (EDVI: 1.78 ± 0.38; ESVI:
0.71± 0.16) compared to controls (EDVI: 1.44 ± 0.33; ESVI: 0.45 ± 0.09) (EDVI:
p=0.075; ESVI: p< 0.01). Taken together, these data indicated dilation and reduced
contractility of the right ventricle. Akap13cKO-MCM mice in the ≥8 week group had only
modestly increased EDVI (1.77 ± 0.32) compared to controls (1.61 ± 0.18) (p>0.05).
However, ESVI remained increased (0.74 ± 0.18) compared to controls (0.56 ± 0.05)
(p<0.05 one-way). These data showed that right ventricular function continued to be
affected over time. Right ventricular function was also evaluated in Akap13Het-MCM mice.
No changes were observed with RV EDVI or ESVI (p>0.05).
When right ventricular EDVI and ESVI were stratified by sex, male Akap13cKO-MCM
mice showed modestly increased EDVI (1.73 ± 0.36) compared to controls (1.52 ± 0.31)
(p>0.05). ESVI was also increased (Akap13cKO-MCM: 0.71 ± 0.19; control: 0.51 ± 0.08)
(p<0.05). These data indicated dilation and impaired contractility of the right ventricle in

90
male Akap13cKO-MCM mice. Female Akap13cKO-MCM mice showed similar but more severe
outcomes. EDVI (1.84 ± 0.34) as well as ESVI 0.75 ± 0.14) were increased in female
Akap13cKO-MCM mice compared to controls (EDVI: 1.47 ± 0.29; ESVI: 0.47 ± 0.10) where
(EDVI: p=0.059 two-way; ESVI: p<0.01). These data suggested dilation and impaired
contractility of the right ventricle. In sum, both male and female Akap13cKO-MCM mice
developed biventricular dilated cardiomyopathy with compensatory left ventricular
hypertrophy and impaired contractility. However, female Akap13cKO-MCM mice showed
increased morbidity since they exhibited more severe cardiac dysfunction than respective
Akap13cKO-MCM males (Table ST.7a).
Right ventricular function in Akap13Het-MCM mice were also stratified based on sex.
Female Akap13Het-MCM mice (n=7) showed no changes in EDVI (Akap13Het-MCM: 1.45 ±
0.12; Control: 1.47 ± 0.10) (p=0.80706), and modestly increased ESVI (Akap13Het-MCM:
0.54 ± 0.050; Control: 0.47 ± 0.037) (p>0.05) (Table ST.7b). Male Akap13Het-MCM mice
(n=4) also showed changes in EDVI (Akap13Het-MCM: 1.95 ± 0.15; Control: 1.56 ± 0.14)
(p>0.05) and modestly increased ESVI (Akap13Het-MCM t: 0.77 ± 0.08; Control: 0.58 ± 0.07)
(p= 0.09) compared to controls (n=11) (TABLE). These data showed that both male and
female Akap13Het-MCM mice had modest dilation of the right ventricles and therefore
showed a mild biventricular cardiomyopathy.
When stratified based on duration post-recombination, male Akap13cKO-MCM mice in
the <8 weeks post-recombination group showed modestly increased ESVI (Akap13cKO-MCM:
0.74 ± 0.19; control: 0.53 ± 0.03) (p>0.05). However, male Akap13cKO-MCM mice in the ≥8
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weeks post-recombination group had increased EDVI (1.73 ± 0.14) compared to controls
(1.47 ± 0.01; p<0.05, one-way). Taken together, these data suggested male Akap13cKO-MCM
mice developed mild right ventricular dilation and contractility defects that partially
improved over time although persisted. Conversely, female Akap13cKO-MCM mice in the <8
weeks post-recombination group showed profoundly increased EDVI and ESVI compared
to controls (Akap13cKO-MCM: EDVI: 1.89 ± 0.2; ESVI: 0.76 ± 0.08; control: EDVI: 1.33 ±
0.26; ESVI: 0.40± 0.06) (EDVI: p< 0.05; ESVI: p<0.001). Female Akap13cKO-MCM mice in
the ≥8 weeks post-recombination group showed modestly increased EDVI (1.8 ± 0.41)
(p>0.05) and ESVI (0.75 ± 0.18) (p>0.05) compared with respective controls (EDVI: 1.71
± 0.16; ESVI: 0.58 ± 0.04). These data showed that female Akap13cKO-MCM mice had a
more severe right ventricular phenotype than male Akap13cKO-MCM mice, and that these
defects were only partially improved with time post-excision (Table ST.8).
Taken together, these data showed biventricular dilated cardiomyopathy with compromised
contractility in Akap13cKO-MCM mice. Akap13Het-MCM mice had a similar but less severe
phenotype compared to Akap13cKO-MCM mice.
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Summary of MRI data
Collectively, these MRI data showed that the Akap13cKO-MCM mice had severely
impaired cardiac function with biventricular dilated cardiomyopathy, increased cardiac
remodeling over time which resulted in compensatory left ventricular hypertrophy, and
impaired contractility. Males were more likely to compensate with cardiac remodeling over
time, however, they decompensated with cardiac stress testing. Females showed a more
severe cardiac phenotype than males from the outset and were not able to adequately
compensate with time or stress. Moreover, female Akap13Het-MCM also exhibited a disease
phenotype while Akap13Het-MCM male mice showed few phenotypic changes. Taken
together, female Akap13cKO-MCM mice demonstrated increased morbidity over male
Akap13cKO-MCM mice under these experimental conditions thus a sex-dependent phenotype
was established.
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Echocardiographic analyses showed impaired cardiac contractility and restrictive
filling pattern of the left ventricle in Akap13cKO mice
Echocardiography (ECHO) is a cardiac specific sonogram that uses ultrasound
(high frequency) waves in order to produce a two-dimensional, three-dimensional, or
Doppler ultrasound heart image on a visual display and is routinely used for heart disease
diagnostics (Anavekar, 2009). Echocardiograms were conducted on anesthetized
Akap13cKO mice and controls in order to assess LV diastolic functional changes. Since LV
dilation with compensatory LV hypertrophic remodeling was most pronounced in the
Akap13cKO-MCM mice ≥8 weeks post-recombination, particularly females, this group was
focused on for analyses. Heart rate, body temperature, and respiration rates were monitored
for each animal during the procedure. Measurements were obtained via a transthoracic
approach from the parasternal long axis view (PSLAX). Relative wall thickness (RWT)
was evaluated in order to categorize the type of hypertrophy exhibited. Relative wall
thickness can be calculated using the measurement from Left Ventricular Posterior Wall at
diastole (LVPWd) and the Left Ventricular End Diastolic Diameter (LVEDD) as follows:

LVPWd was increased in Akap13cKO-MCM mice (n=3) (0.847mm ± 0.024) compared to
controls (n=3) (0.679mm ± 0.038; p<0.05), and Akap13cKO-MCM mice had modestly
increased RWT (Akap13cKO-MCM mice: 0.47 ± 0.036; control: 0.41 ± 0.012; p=0.15 oneway). However, no overall changes in the corrected LV mass (mg) were observed

94
(Akap13cKO-MCM: 93.34mg ± 7.22; control: 90.72mg ± 10.95) (p=0.886). According to the
literature, RWT measurements >0.42 and increased LV mass are criteria for concentric
hypertrophy (Lang, 2006). However, if RWT is increased, but LV mass is unchanged, then
the changes are defined as ventricular remodeling (Sherif F. Nagueh, 2009). Given these
data, the three female Akap13cKO-MCM mice ≥8 weeks post-recombination exhibited left
ventricular remodeling.
Fractional Shortening (FS) is a measure of heart function or contractility and is
calculated by measuring the difference of the End-Diastolic Diameter (EDD) and EndSystolic Diameter (ESD) of the left ventricle. FS is evaluated by the following formula:

FS% were decreased in the Akap13cKO-MCM mice (n=3) (28.67% ± 1.50) compared to
controls (n=5) (41.9 ± 3.67) (p<0.05). Additionally, Akap13cKO-MCM mice had increased left
ventricular volume in diastole (Akap13cKO-MCM: 56.04µL ± 7.38; control: 42.34µL ± 2.79)
(p=0.06 one-way) and systole (Akap13cKO-MCM: 25.69µL ± 5.32; control: 11.0µL ± 1.10)
(p<0.05) which indicated dilation of the left ventricle associated with impaired contractility
(Fig. 2.20a).
Furthermore, the ratio of the early (E)/late diastolic or atrial (A) left ventricular
filling velocities, or E/A ratio, are used to measure left ventricular diastolic function, and
along with mitral deceleration time (DT), grade diastolic dysfunction (where, E/A
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<0.8=Grade I, 0.8-1.5=Grade II, ≥2=Grade III, and DT is reduced) (Fig. S.11). The
transmitral valve inflow creates two separate waves with the E-wave appearing before the
A. In normal hearts, the E-wave should have a larger amplitude than the A-wave (Fig.
S.12). Recordings were taken at the level of the mitral annulus. Here we found Akap13cKOMCM

mice (n=3) had increased E/A ratio (2.93mm/s ± 0.23) compared to controls (n=8)

(1.73mm/s ± 0.12) (p<0.01) (Fig. 3o). These findings were consistent in the AKAP13cKOTOC

mice (n=4) (AKAP13cKO-TOC 3.97 ± 0.64; control: 1.72 ± 0.28; p<0.05 one-way) (Fig.

2.20b-c).
Mitral E-wave Deceleration Time (DT) was decreased in female Akap13cKO-MCM
mice (n=3, both) (Akap13cKO-MCM: 13.40ms ± 2.07; control: 22.08ms ± 1.68; p<0.05) and in
AKAP13cKO-TOC mice (n=4) compared to controls (n=3) (AKAP13cKO-TOC: 19.07ms ± 2.68;
control: 29.58 ± 0.241; p<0.05). When the results from both models and sexes were
combined (n=7) (AKAP13cKO: 13.83 ± 1.72; control: 25.81 ± 1.49; p<0.01) clearly
demonstrated the decreased DT compared to controls (n=10) (Fig. 2.20d,e).
Mitral valve area (MVA) can be used, in part, to assess the stiffness of the left
ventricle. MVA was increased in female Akap13cKO-MCM mice compared to control mice.
(MVA: Female Akap13cKO-MCM: 69.04mm2 ± 16.64; female control: 35.04mm2 ± 2.77;
p=0.1736; AKAP13cKO-TOC: 41.65mm2 ± 6.02; control: 25.42mm2 ± 0.71; p=0.0935;
AKAP13cKO: 62.98mm2 ± 11.06; control: 33.76mm2 ± 3.07; p<0.05). These data suggested
changes concomitant to the increased stiffness of the LV (Fig. 2.20f,g).
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Figure 2.20| Echocardiography (Echo) showed restrictive filling pattern (Grade
III) of the left ventricle in Akap13cKO-MCM mice. a) Akap13cKO-MCM mice (n=3) had
lower fractional shortening percentage (FS%) than control mice (n=5) (p<0.05). b)
Echo, parasternal long axis (PSLAX) view of a control heart. Normal mitral inflow
E- and A-waves shown below.
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Figure 2.20 cont.| Echocardiography (Echo) showed restrictive filling pattern (Grade
III) of the left ventricle in Akap13cKO-MCM mice. d) Echo, E/A ratio increased in
Akap13cKO-MCM mice (n=7) compared to control mice (n=10) (p<0.01). e) Echo, Akap13cKOMCM
mice have decreased deceleration time compared to control mice (p<0.05). f) Echo,
Akap13cKO-MCM mice (n=7) have increased mitral valve area compared to control mice
(n=10) (p<0.05). g) Echo, electrocardiogram (ECG) strip showing (upper panel) control
and (lower panel) Akap13cKO-MCM mice. Akap13cKO-MCM mice exhibited increased heart rate.
Student’s t-test used for statistical analyses.
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Collectively, these echocardiographic data showed that female Akap13cKO-MCM mice
≥8 weeks post-recombination had dilated cardiomyopathy with compensatory hypertrophic
remodeling of the left ventricle, impaired left ventricular systolic function, and diastolic
dysfunction with restrictive pattern (Grade III) of the left ventricle. These findings were
emulated in the AKAP13cKO-TOC mice (combined sexes), and were made even more
apparent when the data from both models were combined. Left ventricular hypertrophy in
the Akap13cKO-MCM mice ≥8 weeks post-recombination, as demonstrated by MRI and
ECHO, was best appreciated by histological cross-section (Fig. S.13).
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ECG analyses suggestive of cardiomyopathy with left atrial enlargement in
Akap13cKO mice
A 3-leads Electrocardiogram (ECG) was performed as an in vivo cardiac functional
assessment to evaluate cardiac electrical activity in anesthetized Akap13cKO-MCM mice
(n=14) compared to control mice (n=18) (Fig. 2.21a,b). Alterations in cardiac electrical
activity can indicate many underlying cardiac pathologies both chronic and acute in nature.
ECG monitoring was performed at two different time points. Again, one group was
monitored at < 8 weeks after cessation of the treatment inducing Cre-excision (either
tamoxifen or doxycycline respective to the Cre), and the other group was monitored at ≥8
weeks post-recombination. Overall, when comparing AKAP13cKO to control mice,
Akap13cKO-MCM mice exhibited tachycardia (Akap13cKO-MCM: 518.64 bpm ± 20.47; Control:
457.56 bpm ± 16.26) (p<0.05), widened QRS intervals (Akap13cKO-MCM: 10.80ms ± 0.62;
Control: 8.74ms ± 0.34) (p<0.01), and prolonged QT intervals (Akap13cKO-MCM QTcB:
63.43ms ± 6.02; QTcF: 37.726ms ± 2.58; Control QTcB: 48.02ms ± 3.34; QTcF:
31.774ms ± 1.1 ) (QTcB : p< 0.05; QTcF: p< 0.05) (Fig. 2.21c). Additionally, QRS
decreased amplitude was observed in Akap13cKO-MCM mice (AKAP13cKO R amplitude:
441.06µV ± 58.36; Control: 643.45µV ± 36.24) (p<0.01). ST segment depression and Twave inversion were detected in AKAP13cKO mice compared to control mice (Akap13cKOMCM

ST height: -16.44µV ± 20.52; Control: 34.18µV ± 9.56; T-amplitude: Akap13cKO-MCM:

-5.27µV ± 20.34; Control: 83.20µV ± 13.87) (ST height: p<0.05; T-amplitude: p< 0.01);
50% of Akap13cKO-MCM mice had T-wave inversion whereas only 14% of control mice
exhibited T-wave inversion (Fig. 2.21d). Furthermore, prolonged P duration in lead II
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(Akap13cKO-MCM: 19.494ms ± 1.12; Control: 16.25ms ± 0.88) (p<0.05) suggested left atrial
enlargement (LAE) in Akap13cKO-MCM mice (Table 2.7). Taken together, these outcomes
are consistent with cardiomyopathy with LAE in Akap13cKO-MCM mice (Table 2.7).
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Figure 2.21| Increased electrocardiogram (ECG) abnormalities in Akap13cKOMCM mice. a) ECG, Control mouse ECG waveform demonstrating a normal
electrical pattern. b) ECG, Akap13cKO-MCM mice showed abnormal ECG waveforms.
c) ECG, corrected QT (QTcF) was increased in Akap13cKO-MCM mice (n=10)
compared to control mice (n=15) (p<0.01). d) T-wave abnormalities (including
inversion) were seen with Akap13cKO-MCM mice compared to controls (p<0.01).
Student’s t-test used for statistical analyses.
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Table 2.7| Summary of EKG p-values. Summary table showing increased ECG
abnormalities in Akap13cKO-MCM mice compared to control mice. When the data were
stratified based on age and time post-recombination, increased significant changes in ECG
were seen with male Akap13cKO-MCM mice. These significant changes were suggestive of
conduction defects, increased risk of adverse cardiac events, and increased risk of atrial
fibrillation in the presence of left ventricular dysfunction (El-Chami MF, Brancato C, Langberg
J, et al. QRS duration is associated with atrial fibrillation in patients with left ventricular dysfunction. Clin
Cardiol 2010;33:132–8.).

5
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When the ECG data were stratified based on sex, male Akap13cKO-MCM mice (n=7)
exhibited tachycardia (523.3 bpm ± 26.09) compared to male controls (n=9) (437.58 bpm ±
12.62) (p<0.05). When these data were stratified based on time after cessation of treatment,
male Akap13cKO-MCM mice (n=3) were more affected at ≥8 weeks (Akap13cKO-MCM: 577.93
bpm ± 17.94; Control: 450.45 bpm ± 16.81) (p<0.01) than at <8 weeks post-recombination
(n=4) (Akap13cKO-MCM: 482.25 bpm ± 30.39; Control: 427.28 bpm ± 16.97) (p=0.187)
(Control: ≥8 week: n=4; <8 weeks: n=5). However, female Akap13cKO-MCM mice (n=7)
showed no differences in heart rate compared to controls (n=7) until ≥8 weeks after
cessation of knock-out inducing treatment, where they trended toward tachycardia
(Akap13cKO-MCM: 554.8 bpm ± 36.53; Control: 441.4 bpm ± 41.62) (p>0.05). Additional
ECG findings indicated striking differences between the sexes: males showed multiple,
significant ECG abnormalities compared to females. These pathological alterations became
increasingly significant with time so that mice of either sex had increased ECG
abnormalities ≥8 weeks after treatment cessation.
Overall, male Akap13cKO-MCM mice exhibited significantly widened QRS interval
(Akap13cKO-MCM: 11.40ms ± 0.84; Control: 8.41ms ± 0.45) (p<0.01) with increased QRS
amplitude (Akap13cKO-MCM: 446.49µV ± 94.66; Control: 577.71µV ± 48.61) (p<0.01) and
prolonged QT (Akap13cKO-MCM: QTcB: 75.18ms ± 9.74; QTcF: 45.51ms ± 5.42; Control:
QTcB: 43.96ms ± 2.08; QTcF: 31.58ms ± 1.38) (QTcB: p<0.01; QTcF: p<0.05). QT was
prolonged even after correction for QRS prolongation. Male Akap13cKO-MCM mice also
showed ST segment depression (Akap13cKO-MCM: -8.13µV ± 16.40; Control: 33.42µV ±
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8.53) (p<0.05) and 43% showed T-wave inversion with an overall flattening of the T-wave
(Akap13cKO-MCM: 4.31µV ± 12.57; Control: 88.94 µV ± 19.02) (p< 0.01) compared to 11%
of control mice (Fig. 2.22).

105

Figure 2.22| Male Akap13cKO-MCM mice showed increased ECG abnormalities. a) ECG,
corrected QT (QTcF) was significantly increased in male Akap13cKO-MCM mice (n=7)
compared to male control mice (n=9) (p<0.05). b) T-amplitude was decreased in male
Akap13cKO-MCM mice (n=7) compared to male control mice (n=9). Student’s t-test used for
statistical analyses.
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At <8 weeks, male Akap13cKO-MCM mice had widened QRS intervals (Akap13cKOMCM

: 11.80ms ± 1.11; Control: 8.36ms ± 0.71) (p<0.05) with a trend toward a prolonged

QT interval (Akap13cKO-MCM: QTcB: 60.98ms ± 9.52; QTcF: 40.91ms ± 5.18; Control:
QTcB: 42.90ms ± 3.60; QTcF: 30.96ms ± 2.43) (QTcB: p= 0.1227; QTcF: p= 0.1461). We
observed a trend in ST depression (Akap13cKO-MCM: -21.82µV ± 24.95; Control: 22.25µV ±
9.32) (p= 0.1586) accompanied by significant T-wave inversion (Akap13cKO-MCM: -3.47µV
± 19.26; Control: 81.25µV ± 31.40) (p<0.05 one-way) in 50% of Akap13cKO-MCM mice
compared to 20% of control mice. At ≥8 weeks we saw a persistent trend toward widening
of the QRS interval (Akap13cKO-MCM: 10.86ms ± 1.21; Control: 8.46ms ± 0.46) (p=0.1459)
with decreased QRS amplitude (Akap13cKO-MCM: 10.13 ± 78.73; Control: 47.38 ± 69.76)
(p<0.05), prolonged QT interval (Akap13cKO-MCM: QTcB: 89.37 ± 12.42; QTcF: 54.73 ±
9.67; Control: QTcB: 45.28 ± 0.91; QTcF: 32.36 ± 0.49) (QTcB: p<0.05; QTcF: p<0.05one-way), and persistent ST depression (Akap13cKO-MCM: 10.13µV ± 12.77; Control:
47.38µV ± 12.02) (p=0.1363) with flattening of the T-wave (Akap13cKO-MCM: 14.68µV ±
11.74; Control: 98.55µV ± 15.81) (p<0.05) and T-wave inversion seen in 33.33% of
Akap13cKO-MCM mice and 0% of control mice.
Female mice showed similar trends with ST depression (Akap13cKO-MCM: -24.75µV
± 37.35; Control: 39.44µV ± 21.17) but were not significant (p=0.1915). However, female
Akap13cKO-MCM mice (n=4) did show significant T-wave inversion compared to controls
(n=4) before 8 weeks post-treatment (Akap13cKO-MCM: -37.72µV ± 64.67; Control:
112.09µV ± 14.77) (p<0.05 one-way) where 50% of female Akap13cKO-MCM mice showed
T-wave inversion, and 0% of control mice showed T-wave inversion. At ≥8 weeks, female
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Akap13cKO-MCM mice (n=3) showed a generalized flattening of the T-wave (Akap13cKO-MCM:
15.66µV ± 6.14; Control: 50.78µV ± 34.74) (P>0.05) compared to control mice (n=4) and
decreased QRS amplitude (Akap13cKO-MCM: 413.50µV ± 12.92; Control: 663.18µV ±
48.39) (p<0.05) (Fig. 2.23).
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Figure 2.23| Female Akap13cKO-MCM mice showed few ECG abnormalities. a) ECG,
corrected QT (QTcF) showed no differences between mice female Akap13cKO-MCM mice
(n=5) compared to female control mice (n=7) (p>0.05). b) T-amplitude was decreased in
female Akap13cKO-MCM mice (n=7) compared to female control mice (n=9) (p<0.05).
Student’s t-test used for statistical analyses.
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Other ECG findings revealed that overall, Akap13cKO-MCM mice had significantly
prolonged P waves on Lead II (Akap13cKO-MCM: 18.87ms ± 1.27; Control: 15.58ms ± 0.64)
(p< 0.05) which indicated left atrial enlargement. When stratified based on sex, both male
and female Akap13cKO-MCM mice had significantly prolonged P waves (male Akap13cKOMCM

: 241.52ms ± 0.97; male Control: 17.28ms ± 0.71; female Akap13cKO-MCM: 19.30ms ±

1.44; female Control: 2.36ms ± 0.83) (male: p<0.05; female: p<0.05).
In summary, these ECG data showed that cardiac electrical activity defects were present in
Akap13cKO-MCM mice. Alterations were consistent with cardiomyopathy and left atrial
enlargement. Moreover, Akap13cKO-MCM males showed more abnormalities on ECG than
Akap13cKO-MCM females.
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Compensatory Tachycardia exhibited in Akap13cKO mice
Next, we evaluated blood pressure, mean arterial pressure, and heart rate in awake
mice via the tail vein. While hypertension can cause cardiomyopathy, we did not anticipate
that Akap13cKO-MCM mice would have hypertension since a conditional, cardiomyocyte
specific knockout was performed thereby reducing off-target effects, such as vascular
contributions. Nonetheless, blood pressure had to be taken into consideration for a
comprehensive assessment of the phenotype. As expected, Akap13cKO-MCM mice (n=6)
exhibited no differences in systolic, diastolic, or Mean Arterial Pressure (MAP) compared
with control (n=8) mice (p>0.05) (Fig. S.14). However, Akap13cKO-MCM mice (n=6)
exhibited compensatory tachycardia (722.33 bpm ± 22.63) compared to control mice
(n=12) (674.83 bpm ± 14.87) (p<0.05) (Fig. S.15). This finding was expected and was
consistent with our HR ECG data.
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Female Akap13cKO mice had increased mortality
Survival analysis suggested that female Akap13cKO-MCM mice had an increased
chance of mortality compared to male Akap13cKO-MCM mice since 40% of female mice died
by 4 months post treatment (2/5 mice) whereas no male mice died of natural causes by this
time point (0/6 mice) (p=0.051; one-way). Of these male mice, 2 were euthanized at 6
months post-treatment for other studies. However, the 4 male mice that were not
euthanized for other studies were still alive at the time this dissertation was written (14
months post-treatment). The 3 surviving female mice were euthanized at 6 months and 9
months post-treatment for other studies (Fig. 2.24). These data, taken together with the
cardiac functional data, suggest that Akap13cKO-MCM mice had failing hearts resultant from
loss of Akap13, and that female Akap13cKO-MCM mice were more likely to succumb to the
genetic insult than males.
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Figure 2.24| Survival Analysis showed increased mortality in female Akap13cKO-MCM
mice. Kaplan-Meier survival curve, Female Akap13cKO-MCM had a 60% survival probability
(p=0.05, one-way). Two out of 5 female Akap13cKO-MCM mice died (2/5 mice). No Male
mice died during the measured time period (0/6 mice). (p=0.05, one-way) by ProductLimit Survival Estimates (SAS).
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PKA activity was decreased in Akap13cKO mice
Phosphotungstic Acid-Hematoxylin (PTAH), a stain used in histology labs for
staining striated muscle fibers, such as cardiac tissue (Naaijenkins, 2015) revealed the
same granular appearing cardiomyocytes appreciated with H&E. No overt increase in
fibrosis was noted, but unequal staining of the cardiomyocytes in the Akap13cKO-MCM mice
compared to controls was observed (Fig. S.16). Additionally, we stained Akap13cKO-MCM
heart tissue sections with Masson’s Trichrome, a commonly used three-color stain that
results in blue collagen, pink to red muscle fibers, cytoplasm and erythrocytes, and black
nuclei. These results suggested an increase in collagen and dysmorphic cardiomyocytes in
Akap13cKO mice ≥8 weeks post-recombination which also suggested disease progression
over time as demonstrated by MRI (Fig. S.17). These special stains (PTAH and
Trichrome) highlighted the morphological changes at the cellular, tissue, and organ levels
that Akap13cKO mouse hearts developed including ventricular chamber dilation and
hypertrophic remodeling with increased collagen in Akap13cKO-MCM mice ≥8 weeks postrecombination. Dysmorphic cardiomyocytes were also observed which indicated that loss
of Akap13 resulted in structural and potentially functional cardiomyocyte and organellar
changes and cytoskeletal disruption.
Over the years, robust data have shown cAMP-dependent Protein Kinase A (PKA)
and

RhoA to have highly conserved, defined roles in cytoskeletal arrangement and

regulation of the cardiac sarcomere (Yamasaki, 2002) (Mayers, 2010). Likewise, AKAP13
interaction with both PKA and RhoA have been well described in the literature, and were
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therefore key targets for AKAP13’s role in cardiomyocyte signaling pathways and
maintenance of the cardiac sarcomere. However, PKA and RhoA do not act in
coordination with each other. In fact, data have shown PKA inhibits RhoA as well as
lysophosphatidic acid (LPA) stimulation of SRF via disruption of actin filaments (Sauzeau
et al., 2000) (Ellerbroek et al., 2003) (Qiao, 2003) (Oishi, 2012). In order to assess general
PKA activity (not isoform specific), we performed an enzyme-linked immuno-absorbent
assay (ELISA) with Akap13cKO mouse heart extracts compared to control heart extracts.
PKA was found to be significantly decreased in the cardiac isolates from Akap13cKO mice
compared to control mice (Fig. 2.25) (p<0.05). Moreover, initial findings suggested that
RhoA activity was not decreased in Akap13cKO-MCM heart extracts (n=3) compared to
control (n=3) (p>0.05) (Fig. 2.26). These results were consistent with prevailing data, and
suggested that loss of Akap13 dysregulated PKA activity more profoundly than RhoA
activity.
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Figure 2.25| PKA activity levels decreased in Akap13cKO mice. Upper panel, PKA
activity measured by enzyme-linked immunosorbent assay (ELISA) showed decreased
PKA activity in Akap13cKO mice compared to control mice (p<0.05). Student’s t-test used
for statistical analyses. Lower panel, Diagram demonstrating the cAMP-dependent PKA
pathway inhibition of the RhoA/ROCK pathway (left) and the de-repression of the
RhoA/ROCK pathway with decreased activity of the cAMP-dependent PKA pathway
(right).
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Figure 2.26| RhoA activity was not altered in Akap13cKO mice. RhoA activity measured
by enzyme-linked immunosorbent assay (ELISA) showed no significant changes in RhoA
activity in Akap13cKO-MCM mice (n=3) compared to control mice (n=3) (p>0.05).
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Proteomic and transcriptomic analyses indicated damage to key pathways required
for normal actin assembly and mitochondrial function
To better understand AKAP13’s mechanism of action, the Segars lab previously
demonstrated AKAP13 binding and interaction with the following transcription factors: cFos, c-Jun, SRF, CREB, PPARγ and ERα. Since it has been shown that AKAP13 is
essential for embryonic development (Mayers, 2010), we hypothesized that AKAP13’s
ability to bind to the aforementioned transcription factors was a critical regulatory step for
appropriate gene regulation. In the targeted cardiac knockout of Akap13, these
transcription factors, while likely present in normal quantities, may have been unable to
effectively regulate genes in the absence of AKAP13. Given this hypothesis, we evaluated
the cardiac proteome and transcriptome of Akap13cKO-MCM mice (n=6) from heart protein
(n=3) and RNA isolates (n=3) compared to heart isolates from age and sex-matched
control mice (n=3, both).
Proteomic and RNAseq data mining and pathway analyses were performed using
Ingenuity Pathway Analysis (IPA), Metacore, and Pathway Studio to ensure the majority
of publicly available bioinformatics software knowledge bases had been adequately
queried. Proteomics analyses identified significant disruption of cellular pathways
including mitochondrial oxidative phosphorylation as well as cytoskeletal dynamics (Fig.
2.27).
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Figure 2.27| Proteomics analysis demonstrate mitochondrial, cytoskeletal, and
transcriptional pathway disruption in Akap13cKOmice. Proteomics analysis, cardiac
tissue from 5-month-old control (n=3) and Akap13cKO (n=3) mice was collected posttreatment (tamoxifen/doxycycline where appropriate). The pathway analysis demonstrated
pathological changes in major mitochondrial processes (oxidative phosphorylation), and
changes to the cytoskeleton.
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PKA, specifically the RIIA isoform (Prkar2a), was found to have decreased
peptide counts in our proteomics dataset in Akap13cKO-MCM heart protein isolates compared
to control protein isolates (Supplemental). However, the RIA isoform (Prkar1a) was found
to be increased in the same proteomic dataset, and is likely a compensatory reaction since
AKAP13 preferentially binds to RIIA, but may bind to RIA when it has increased
concentrations (Gold, 2006). RhoA levels were not found to be statistically altered in the
Akap13cKO-MCM heart protein isolates compared to control protein isolates. These data
supported the results from our PKA and RhoA functional analyses.
Moreover, several proteins partly responsible for mitochondrial fusion, cristae
formation, cristae junctions, and mitochondrial transport including MFN1, subunits from
the MICOS complex, TOM40, TIM10, and VDAC1 along with cytoskeletal proteins such
as Class IIb Beta-Tubulin, and scaffold proteins such as alpha-1-syntrophin (Snta1) were
reduced in Akap13cKO-MCM mice compared to control mice. Interestingly, Snta1 has been
linked to long-QT syndrome like the ECG phenotype exhibited by the Akap13cKO mice.
Likewise, many of the dysregulated genes had common transcriptional regulators including
c-Fos, SRF, CREB, PPARγ and ERα (Table ST.9).
PGC-1 and ERR-induced regulator in muscle protein 1 (Perm1) protein levels were
significantly decreased in Akap13cKO-MCM mouse heart extracts compared to control heart
extracts per proteomic analysis. This was particularly interesting since PGC-1 has been
implicated in cardiac mitochondrial dynamics. Cardiac specific PGC-1 knockout induces a
strikingly similar mitochondrial phenotype as cardiac specific Akap13 knockouts.
Moreover, PGC-1 was shown to activate MFN1 transcription, a protein also decreased in
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Akap13cKO mice, via the transcription factor Estrogen-Related Receptor α (Martin, 2014).
Other AKAPs, including the mitochondrial AKAP1, also had decreased peptide counts in
Akap13cKO-MCM mice compared to control mice.
Similarly, RNA sequencing (RNAseq) showed that AKAP5 was downregulated in
Akap13cKO-MCM mice compared to control mice. RNAseq analysis also showed
dysregulation of mitochondrial genes including MT-ND3, Slc7a1, and Lars2 as well as
cytoskeletal genes such as Tuba4a and Mylk4, and perturbations of several transcription
factors including E2F1 and Foxc1. Notably, the mitochondrial matrix protein Adenylate
Kinase 4 (AK4) was downregulated in both RNAseq and proteomics datasets. (Table
ST.10). Furthermore, key sarcomeric genes known for their involvement in the
development of dilated cardiomyopathy were also shown to be dysregulated (Fig. 2.30).
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Decreased mitochondrial membrane potential in cardiomyocytes isolated from
Akap13cKO-TOC mouse hearts
Given the striking mitochondrial phenotype observed in many of Akap13cKO-TOC
cardiac mitochondria, including partial or complete loss of cristae (Fig. 2.28), we sought to
quantify the function of the mitochondria in vitro. To this end, we isolated cardiomyocytes
from Akap13cKO mouse hearts and stained them with live cell markers, Mitotracker green
and MitotrackerCMX ROS, to quantify the mitochondrial membrane potential. The adult
cardiomyocytes were observed using confocal microscopy, and even without
quantification, the Akap13cKO mice appeared to have increased mitochondria, but with
decreased fluorescence intensity. After quantification, the fluorescence intensity ratio was
found to be significantly decreased (p<0.01) in live mitochondria in Akap13cKO
cardiomyocytes (n=60) compared to control cardiomyocytes (n=60) (Fig. 2.29). These
results indicated that mitochondria in Akap13cKO cardiomyocytes had reduced membrane
potential compared to mitochondria in control cardiomyocytes. Furthermore, live cell
imaging showed an overall increase in the number of mitochondria in the Akap13cKO
cardiomyocytes in spite of the reduction in membrane potential (Baig-Ward, 2016, in
preparation). Taken together, these data suggested that the mitochondria in Akap13cKO
isolated cardiomyocytes had decreased membrane potential compared to cardiomyocytes
isolated from control mice. The increase in the mitochondrial population suggested a
compensatory reaction, or a possible disruption in mitochondrial fusion/fission dynamics.
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Figure 2.28| Electron microscopy revealed significant loss of mitochondrial cristae in
Akap13cKO mice. Electron micrograph, Control mouse cardiac tissue (left) demonstrated
normal mitochondria with cristae, as expected. Akap13cKO mouse heart tissue (right)
showed loss of mitochondrial cristae in many of the mitochondria.
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Figure 2.29| Decreased mitochondrial membrane potential in adult cardiomyocytes
isolated from Akap13cKO mouse hearts. a) Confocal microscopy, Fluorescence intensity
ratio (as determined by MitotrackerCMX ROS and Mitotracker green ratios) was assayed
as a measure of mitochondrial membrane potential. Akap13cKO cardiomyocytes (n=60) had
decreased mitochondrial membrane potential when compared to control (n=60) (p<0.01).
B) Control (upper panel) and Akap13cKO (lower panel) isolated cardiomyocytes are
pictured.
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Hallmarks of heart failure were detected in Akap13cKO-MCM mice
Myocyte Enhancer Factor 2c (Mef2c) is a developmental gene that encodes the
50kDa protein (MEF2C) essential for cardiogenesis. Initial Mef2c transcript analysis via
RT-qPCR suggested Mef2c upregulation in Akap13cKO-MCM mouse heart isolates compared
to controls (Fig. S.18). Similarly, RNAseq showed upregulation of myosin and other
cytoskeletal and cardiac developmental genes (such as BMP10) in Akap13cKO-MCM mice
compared to control mice which suggested a fetal gene response as reported in the heart
failure literature (Dirkx, 2013) (Table ST.11). Furthermore, RNAseq demonstrated
upregulation of Cyp2e1, a cytochrome implicated in heart disease and shown to be
increased in dilated cardiomyopathy, and dysregulation of sarcomeric genes also known to
be involved in dilated cardiomyopathy (Lu, 2012) (Fig.2.30). Other hallmarks of heart
failure included increased levels of estrogen receptor alpha (ERα) and increased
complement components.
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Figure 2.30| Multiple sarcomeric components were altered in Akap13cKO-MCM mouse
hearts. RNAseq, next generation sequencing of RNA isolated from 5-month-old control
(n=3) and Akap13cKO-MCM (n=3) pathway enrichment analysis identified several
fundamental pathways affected in Akap13cKO-MCM mice including cytoskeleton/sarcomeric
remodeling, fetal genes, cell adhesion, and calcium handling which demonstrated a dilated
cardiomyopathy/heart failure phenotype.
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PKA pathway, Opa1, and critical transcription factors altered in Akap13cKO mice
Yeast two-hybrid analyses previously performed in our lab (unpublished data)
suggested high stringency AKAP13 interactions with multiple mitochondrial and
cytoskeletal proteins including AFG3L2 (paraplegin-like protein), COX8A (cytochrome c
oxidase subunit VIII) and CTNNAL1 (catenin alpha like-1) which indicated that a physical
interaction may be possible with these proteins (Figure 2.31a). Similarly, our lab
previously demonstrated Akap13 localization to actin filaments (Fig. S.19) in H9c2 rat
cardiac cells. Mitochondria and actin are known to interact for normal mitochondrial
morphology, movement, and function (Istvan R. Boldough, 2006). In fact, F-actin
filaments transiently assemble on the outer mitochondrial membrane during the process of
fission (Sunan Li, 2015). Furthermore, AFG3L2, a suggested AKAP13 binding partner, is
an m-AAA protease involved in Opa1 cleavage. In the absence of AFG3L2, Opa1 isoforms
are not properly processed, and results in fragmented mitochondria and reduced
mitochondrial calcium uptake (Kondadi, 2014) (Maltecca, 2012 ).
To test whether AKAP13 is physically associated with the mitochondria, we
performed western blot analysis using mitochondria isolated from control mouse hearts.
The western blot showed two discrete, albeit faint, 310kDa AKAP13 bands suggesting that
AKAP13 may be closely adherent to, or contained within, the mitochondria (Figure 2.31b).
Given the size of the largest AKAP13 isoform (~310 kDa), it is doubtful that AKAP13
migrates into the mitochondria. However, due to mitochondrial interaction with F-actin,
and AKAP13’s ability to bind F-actin and other actin binding proteins, it is possible that
AKAP13 is able to dock on the outer mitochondrial membrane and bring other effectors,
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such as RhoA, CREB, PPARγ, PKA, PKN, PKD or the like closer to their targets (Lenoir,
2014) (Taglieri, 2014).
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Figure 2.31| AKAP13 protein detected in mitochondrial fraction isolated from
mouse heart tissue. a) Western blot, AKAP13 (~310kDa) was detected using an
anti-AKAP13 polyclonal antibody in isolated mitochondria from control mouse
hearts (n=3). Band tracing (ImageJ, lower panel) analysis detected the AKAP13
band. b) Schematic diagram of a mitochondria showing mitochondrial proteins
affected in proteomics and RNAseq analyses. AKAP13 yeast two-hybrid putative
binding partner indicated (yellow circle).
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As mentioned above, Opa1, a dynamin-like 120kDa GTPase, migrates to the inner
mitochondrial membrane, requires MFN1 for mitochondrial fusion (Cipolat, 2004), and is
involved in cristae formation and apoptosis. Since cristae were absent in many
mitochondria from cardiac tissue collected from Akap13cKO-MCM mice, MFN1 protein levels
were decreased in our proteomics analysis, and high stringency yeast two-hybrid analyses
indicated AFG3L2 as a putative AKAP13 binding partner, we performed RT-qPCR to
assess the transcript levels of Opa1 in Akap13cKO-MCM mouse hearts compared to control
hearts. Opa1 transcripts were significantly reduced in AKAP13cKO mice compared to
controls which suggested Opa1 was down-regulated in Akap13cKO-MCM mice (p<0.01) (Fig.
2.32). Additionally, Opa1 transcript levels were quantified from Akap13 siRNA knocked
down H9c2 cells (Figs. S.20, S.21) between 12 and 24-hours post-lysophosphatidic acid
(LPA) treatment by RT-qPCR. Notably, AKAP13 is known to act downstream of LPA
(Mayers, 2010). Initial findings suggested that LPA upregulated Akap13 (Fig. 2.33), as
expected, but also upregulated Opa1 (Fig. 2.34). Both Akap13 and Opa1 transcript levels
increased with time. Similarly, previous studies have shown that LPA stimulates serum
response factor (Srf), a transcription factor with a known role in immediate-early gene
transcription, cardiac development, and the target of several key pathways involved in cell
growth and differentiation, such as the MAPK pathway. For review, see Zarubin and Han
(Han, 2005). We performed RT-qPCR to assess Srf transcript levels from Akap13cKO-MCM
and control mouse heart isolates. Srf was downregulated in Akap13cKO-MCM mouse hearts
compared to control mouse hearts (data not shown). These experiments were repeated in
AKAP13 siRNA knocked down H9c2 cardiac cells, which also showed reduced Srf
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message (p<0.05) (Fig. 2.35). These data were of particular interest since knockout of Srf
results in embryonic lethality with disrupted cardiac sarcomeres (Miano, 2004) much like
global Akap13 knockout (Mayers, 2010).
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Figure 2.32| Mitochondrial fusion protein, Opa1, gene expression levels reduced in
Akap13cKO mouse hearts. RT-qPCR, Optic atrophy 1 (Opa1) is a gene whose protein
product migrates to the inner mitochondrial membrane, and is partly responsible for
mitochondrial morphology and function, including cristae formation and mitochondrial
fusion. Opa1 relative gene expression was decreased in Akap13cKO-MCM mouse hearts (n=3)
compared to control mouse hearts (n=3) (p<0.01). Student’s t-test used for statistical
analyses.
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Figure 2.33| LPA treatment increases Akap13 mRNA expression in H9c2 rat
cardiomyoblasts. Results shown demonstrated previous findings from our group (Mayers,
2010). LPA treatment increases Akap13 transcript levels in Akap13 siRNA knocked down
H9c2 cells (p<0.01). Student’s t-test used for statistical analyses.
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Figure 2.34| LPA treatment increased Opa1 relative gene expression in Akap13 siRNA
knocked down H9c2 rat cardiomyoblasts. RT-qPCR, Pkn1 and Opa1 transcript levels
were quantified in Akap13 siRNA knocked down H9c2 rat cardiomyoblasts post
lysophosphatidic acid (LPA) treatment. Pkn1 transcript levels were unchanged after LPA
treatment of Akap13 siRNA knocked down H9c2 cells. Opa1 transcript levels were
increased in Akap13 siRNA knocked down H9c2 cells.
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Figure 2.35| Srf relative gene expression reduced in Akap13 siRNA knocked down
H9c2 rat cardiomyoblasts. RT-qPCR, Serum response factor (Srf), a transcriptional
activator (binds to serum response element (SRE)). Srf transcript levels were quantified in
Akap13 siRNA knocked down H9c2 rat cardiomyoblasts. Srf was significantly decreased
in Akap13 siRNA knocked down H9c2 rat cardiomyoblasts (n=3) (p<0.05) compared to
control cells (n=3).
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Further global assessment of the proteins and genes down regulated in both the
proteomics and RNAseq datasets revealed common transcription factors for many of the
genes including Elk-1 (14 genes) and Estrogen-Related Receptor α (13 genes) (Baig-Ward,
2016, in preparation). These transcription factors were implicated only in proteins
downregulated in our proteomics dataset. They were not indicated in any of the
upregulated genes or proteins from either the RNAseq or Proteomics datasets. However,
SRF was mostly found in genes that had been upregulated indicating that this transcription
factor may have been switched “on” by either loss of upstream repression (via PKA),
dysregulation of co-factors such as ternary complex factors (Elk-1), or pathway
redundancy.
Collectively, these data suggested dysfunction in mitochondrial genes, related
proteins, and in critical cytoskeletal and cardiac genes resultant from the loss of Akap13 in
cardiac tissue. Furthermore, preliminary studies have suggested that LPA treatment was
able to rescue both Akap13 and Opa1 in Akap13 siRNA knocked-down H9c2 cardiac cells,
and acts upstream of SRF. Moreover, Srf transcript levels were also found to be reduced in
both Akap13cKO-MCM mouse heart extracts as well as Akap13 siRNA knocked-down H9c2
cells.
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AKAP13 modulated SRE- and Cre-luciferase activation
Given the possible AKAP13/mitochondrial interaction, roles of both RhoA and
PKA in mitochondrial dynamics including motility (Istvan A. Boldough, 2006) and cardiac
signaling, and to further examine our hypothesis that transcription factor interaction with
AKAP13 is key for appropriate gene regulation, we performed SRE-luciferase (SRE-luc)
and CRE-luciferase (Cre-luc) assays. H9c2 cells were serum deprived in 0.5% fetal bovine
serum (FBS) for 20 hours. Cells were then transfected with either 0ng, 125ng, 250ng, or
375ng full length Akap13 expression vector as well as SRE-luc (Promega) according to
manufacturer directions (Promega, FuGENE6). Transfected cells either received no
treatment or were treated with 10uM LPA. Fold change in SRE-luc activation was then
measured in the cell lysates. In support of previous findings, these control experiments
showed that SRE-luc activation was proportional to the concentration of AKAP13, with
the largest fold change in SRE-luc activation seen after 375ng of AKAP13 combined with
LPA treatment (Fig. S.22). Next, we wanted to ascertain which region of AKAP13
demonstrated the most robust SRE-luc activation. To this end, we transfected H9c2 cells
with two separate regulatory regions of AKAP13 to deduce which domain was responsible
for SRE-luciferase activation. We transfected the cells with either empty vector (RSV-0),
the GEF domain of AKAP13 (Lbc), or the nuclear hormone interacting domain (NRID)
(refer to Fig. S.3a for map). Cells were then treated with either Epinephrine or LPA. SREluc activation showed an almost 3.5-fold activation with the GEF domain plus LPA
treatment (p<0.05). Less activation of SRE-luc was noted with the NRID. Conversely,
epinephrine showed little change over control except for the NRID where it showed SRE-
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luc repression (Fig. S.23). These experiments suggested that the GEF domain has the most
robust SRE-luc activation of the domains queried, and was acting downstream of LPA.
Furthermore, the results with epinephrine were particularly interesting since the G-protein
coupled (GPCR) alpha -1A adrenergic receptors were downregulated in our RNAseq
dataset. Since adrenergic receptors are known to signal through PKA/CREB, we performed
a CRE-luc assay. H9c2 cells were serum deprived in 0.5% fetal bovine serum (FBS) for 20
hours. Cells were then transfected with either 0ng, 125ng, or 250ng, of full length Akap13
expression vector. An 8-fold CRE-activation dose-response was seen when transfected
with 250ng of AKAP13.
In summary, these data confirmed previous reports that AKAP13 acted downstream
of LPA in H9c2 cells and showed robust activation of CRE-luc. Furthermore, these
findings support the conclusion that AKAP13 played a key role in multiple pathways
including interaction with AFG3L2 in regulation of mitochondrial fusion, and through a
more regulatory level via interactions with SRF, CREB, and other transcription factors
(Fig. 2.36).

138

Figure 2.36| Working molecular mechanism. AKAP13 is known to modulate
transcription factors and nuclear hormone receptors to affect gene expression.
Additionally, AKAP13 rectifies cAMP-dependent PKA and RhoA signaling pathways
dependent upon the metabolic needs of the cell. In the absence of AKAP13, gene
expression is altered giving way to pathway dysregulation and ultimately a pathological
gene program. Imbalance in the cAMP-dependent PKA and RhoA pathways would result.
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CHAPTER 3: Discussion and Conclusion
We established an inducible, cardiac-specific Akap13cKOmouse model using two
different Cre-recombination strategies (α-MHC-MerCreMer and Tnnt2-rtTA; TetO-Cre).
Akap13cKOmice developed a biventricular dilated cardiomyopathy with compensatory
hypertrophic remodeling of the left ventricle, decreased left and right ventricular systolic
function, and abnormal left ventricular diastolic function as well as dilated left atria.
Specifically, Akap13cKOmice developed significantly reduced LVEF (both at rest and with
dobutamine-induced stress), increased mass and volume indices, dilated ventricular
chambers, reduced fractional shortening, alterations in E/A ratio and deceleration time
indicating diastolic dysfunction with restrictive filling of the left ventricle, abnormal ECG
including prolonged P duration, QRS, and QT intervals, and alterations in ST segments.
Moreover, Akap13cKO mice exhibited compensatory tachycardia. The severity of the
cardiac phenotype, both early (<8 weeks post-induction of Cre-recombination) and as the
disease progressed (≥8 weeks post-recombination), developed in a sex-dependent manner.
Female Akap13cKO mice displayed a more severe cardiac phenotype and were more likely
to die post-recombination. Of note, ECG abnormalities were less prominent in female
Akap13cKO mice.
Ultrastructurally, Akap13cKO heart tissue showed significantly disrupted sarcomeres
and mitochondria. For much of the explanted cardiac tissue, sarcomeres were
unrecognizable with partial z-discs punctuated throughout. Mitochondria were increased in
number, and were of differing sizes, some smaller than normal, others considered mega-
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mitochondria, and swollen. The majority of the mitochondria observed were completely or
partially lacking cristae, and some were missing their outer membrane. Lamellar inclusions
and increased lipids were also seen. Moreover, Akap13cKO H&E stained cardiac tissue
sections also demonstrated altered sarcomeres, as did immunohistochemical analyses.
Dilated left ventricles were best appreciated in histological cross-section.
Confocal microscopy of live adult cardiomyocytes showed significantly decreased
mitochondrial membrane potential and significantly increased numbers of mitochondria in
Akap13cKO adult heart cells compared to controls. Confocal analyses of H9c2 rat
cardiomyoblasts with fluorescently labeled anti-AKAP13 and FITC-phalloidin (F-actin)
showed AKAP13 localization to actin, as previously reported (Mayers, 2010).
Furthermore, Western blot analysis of isolated cardiac mitochondria showed faint
AKAP13 bands. These data suggested that AKAP13 may be closely adherent to the
mitochondria via F-actin filaments, or may even migrate into the mitochondria. Given the
size of the largest AKAP13 isoform (~310 kDa), migration into the mitochondria is
unlikely. However, the smallest isoform, Brx (~170 kDa), is known to enter the nucleus.
Other AKAPs, such as AKAP1, have established roles in mitochondrial dynamics (Jun,
2016). Additional studies with electron microscopy and immuno- or nanoparticle labeled
AKAP13 antibodies would be an informative future study. Moreover, super-resolution
microscopy could be performed in order to establish if AKAP13 localizes to mitochondria,
and under what conditions.
The striking similarity of our results to the human dilated cardiomyopathy literature
suggested that the Akap13cKO model is a novel mouse model for targeted and potentially
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translational research on cardiomyopathy, and is in line with the mission of the National
Institutes of Health. Mitochondrial dysfunction is a known cause of cardiomyopathy,
especially DCM. It has been reported that upwards of 600 rare genetic variants, including
mitochondrial genes, have been associated with the various cardiomyopathies. This
complexity is compounded by variable penetrance and incomplete expression,
environmental factors, and the involvement of multiple signaling pathways and organelles
(Jacoby, 2011) (Chen, 2012). Mutations in mitochondrial genes and proteins, such as
mitochondrial fusion protein, OPA1, can lead to severe cardiac pathology (Chen, 2012).
While mitochondria are dynamic organelles with short half-lives and are prone to
morphological changes in disease states, such as alterations in size and cristae, few
diseases, other than primary mitochondrial diseases, have shown the significant
ultrastructural pathology similar to our data described here. The prominent ultrastructural
alterations seen in the Akap13cKO mouse model appear to be even more severe than those
observed in many primary mitochondrial diseases. Given these data, a central regulatory
role for the AKAP13 protein may be implicated.
Phenotypic changes in murine models deficient in Opa1, Srf, Creb-1, and PGC1α/β have shown ultrastructural and cardiac alterations similar to, but not as severe as, the
Akap13cKO mouse model (Chen, 2012) (Miano, 2004) (Watson, 2010) (Arany, 2005)
(Leone, 2005). In order to thoroughly investigate the genes and gene products altered in
AKAP13cKO mouse heart extracts in an unbiased manner, we performed proteomic and
RNAseq analyses and RT-qPCR on identified gene targets. Ingenuity Pathway Analysis
(IPA), Metacore, and Pathway studio analyses were performed on our differentially
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expressed proteomic and RNSseq derived genes. Dysregulation of key genes and proteins
involved in oxidative phosphorylation, cytoskeletal remodeling, regulation of the actin
cytoskeleton by Rho GTPases, and cardiac dysfunction were indicated (p<0.001). Given
these data, Srf transcript levels were assessed by RT-qPCR and were found to be reduced
in Akap13cKO mice and Akap13 siRNA knocked down H9c2 cells (p<0.05, both). Similarly,
Opa1 transcript levels were assessed and were reduced in Akap13cKO mice heart extracts
and Akap13 siRNA knocked down H9c2 cells (p<0.05, both).

Likewise, decreased

peptides for Perm1 (PGC-1 and ERR-induced regulator) were indicated in Akap13cKO mice
compared to control mice (p<0.001). Given these data, we do not suspect that the
pathological sarcomeric and mitochondrial changes observed in AKAP13cKO mice were
secondary to heart failure, DNA damage response or other off target or treatment effects.
Decreased expression of key target genes (Srf, Opa1) and gene products (MFN1, Perm1)
were concomitant with the loss of Akap13. These data indicated that AKAP13 may be a
key regulatory protein in cardiomyocyte signaling pathways involved in maintaining the
cardiac sarcomere and mitochondrial dynamics.
Moreover, treatment with LPA, a known activator of AKAP13, RhoA, and SRF,
upregulated AKAP13 expression in control and AKAP13 siRNA knocked down H9c2 rat
cardiomyoblasts consistent with previous reports (Mayers, 2010). Additionally, LPA
treatment increased SRE-luciferase activation in an AKAP13 dose-dependent manner.
Higher doses of AKAP13 resulted in increased SRE-luciferase activation. Additionally,
LPA treatment increased Opa1 message in Akap13 siRNA knocked down H9c2 cells
which suggested a common pathway between AKAP13 and OPA1. To probe downstream
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of LPA receptors, Rho A and PKA activities were assayed in Akap13cKO mouse heart
extracts compared to control heart extracts. Enzyme-linked immuno-absorbent assay
(ELISA) showed decreased PKA activity but unchanged RhoA activity. Furthermore,
PKAR2A, the PKA isoform that AKAP13 preferentially binds to, was decreased in our
proteomics dataset while PKAR1A was increased in a seemingly compensatory reaction.
Mybphl, Myl7, Myl4, Mef2c and other genes with regulatory roles in heart development
were found to be upregulated in Akap13cKO mice. It is possible that a fetal gene response
was seen with Akap13cKO as an attempt to overcome the genetic insult, and protect the
heart from further damage (RNAseq figure-table). A fetal gene response is often
accompanied by heart failure (Dirkx, 2013) emphasizing the profound effect that the loss
of Akap13 had on the adult heart. Taken together, these data suggested that Akap13 had an
ongoing role in the adult murine heart, and was involved in cell signaling and pathway
integration via interaction with actin and actin-associated proteins, and sarcomeric
structure and organization via precise modulation of the PKA/RhoA pathways.
Our findings are supported by other reports which have also suggested that actin, desmin,
SRF, RhoA, MEF2c, and intracellular Ca2+ are involved in sarcomere formation, cardiac
signaling, dilation, and contractility (Mayers, 2010) (Greenstein, 2011); perturbations of
these can lead to cardiomyopathy and other cardiac defects (Jacoby, 2011) (Miano, 2004).
It is likely that expression and signaling involving these common pathway components are
altered with the loss of Akap13, as we have previously reported (Koide, 2015) (Mayers,
2010). Notably, Protein A-Kinase Anchoring Proteins (AKAPs) are a key factor in
cardiomyocyte development and serve as regulators of many signaling pathways. The
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regulatory subunit of PKA, as mentioned earlier, is a known substrate of AKAPs. AKAPs
bind the regulatory subunit of PKA and localize the bound PKA to discrete subcellular
micro-niches allowing spatiotemporal regulation of various cell signaling cascades (such
as those that utilize cAMP as a second messenger). That is, AKAPs act as scaffolds to
sequester PKA and other molecules to distinct areas of the cell, and are involved in
signaling crosstalk. This dissertation has demonstrated that the mitochondria and cardiac
sarcomere may be additional target sites for AKAP13. However, substrate sequestration is
not the sole function of every AKAP; functionality is influenced by the abilities of the
individual AKAP. Furthermore, the active role of AKAPs in cell signaling are not limited
to a particular type of cell or tissue; AKAPs have been shown to be important pathway
components, from the plasticity of neurons to cardiomyocyte development to stimulating
the production of cytokines and even cancer (aRubino 1998). The presence of AKAPs in
various cell types emphasizes the importance of the active role of AKAPs in cell signaling
beyond that of a simple scaffolding protein. However, Akap13 is a unique AKAP: it is the
only AKAP that has been found to have guanine nucleotide exchange factor (GEF) activity
and modulate nuclear hormone receptors. The evolutionary conservation and widespread
expression of Akap13 along with its central role in coordinating otherwise chaotic
signaling pathways suggest a critical if not a fundamental role in normal signaling crosstalk (Welch, 2010).
We interpreted these data to suggest that loss of AKAP13 may lead to reduction in
transcription factor signaling, and specifically focused attention on SRF and CREB. These
two factors are known to regulate crucial proteins involved in mitochondrial function, such

145
as OPA1, which was greatly reduced in the cKO cells. In support of a critical role of
AKAP13 upstream of these factors, targeted loss of function of SRF (Miano, 2004) and
OPA1 (Chen, 2012) produced a murine cardiac phenotype strikingly similar to the
AKAP13 phenotype we observed. The similarity of phenotypes observed, the reduction in
transcripts in the cKO cells, and the functional data regarding AKAP13 in H9C2 cells,
suggest a mechanism whereby reduction in AKAP13 leads to impairment of a critical
transcriptional mechanism regulating mitochondrial function.
One possible limitation to the interpretation of our results is that functional data in
mice can be difficult to obtain and is a potential drawback to any cardiac study. In recent
years, increasingly precise functional equipment and software have been designed and
utilized for rodent functional testing. Because of this, various interpretations of functional
tests can be found in the literature, but no real repository of rodent standard values, other
than the paucity of data found in the Mouse Phenome Database published online by The
Jackson Laboratory (Bar Harbor, ME) exists. The datasets currently found in the Mouse
Phenome Database are often incomplete or obtained on small sample sizes. Because of
this, the littermate and within-line sibling controls used in this dissertation were considered
the best indication of standard values by which to directly compare our model. Notably, we
have been asked by the MRI mouse core director at the National Heart Lung and Blood
Institute (NHLBI) National Institutes of Health (NIH) (Bethesda, MD) to include our
control mice data in a functional report to help establish mice reference values for MRI.
Similarly, electrocardiogram (ECG) interpretation can vary from animal to animal, and
even strain to strain. It has been shown in the literature where the T wave in lead I is
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negative (Boukens, 2014). However, other reports (Sadhegi, 2002) (Ho, 2011), as well as
our own data have indicated that the T waves, similar to humans, are more often positive in
lead I. As stated above, normal values were established using the littermates and siblings
of the Akap13cKOmice. Statistical analyses and waveform interpretations were established
per in depth literature review and the expert opinion of our cardiology collaborator (Dr.
Alessandra Broferrio, MD) at NHLBI, NIH.
In conclusion, our data answered the question we had at the outset of this
dissertation: Does AKAP13 have a role in the adult mouse heart? The data set forth in this
dissertation identified Akap13 as a critical gene required for normal adult mouse cardiac
function and morphology. Akap13 knockout lead to biventricular dilated cardiomyopathy
with severely disrupted sarcomeric and mitochondrial phenotypes. Female Akap13cKO mice
exhibited a more severe cardiac phenotype with increased risk of morbidity post-induction
of genetic recombination. Female Akap13Het-MCM mice also showed cardiac abnormalities
whereas male Akap13Het-MCM mice did not. Furthermore, AKAP13 binds numerous
transcription factors, such as c-fos, c-Jun, ERα, and CREB, a ubiquitous transcription
factor in the absence of which produces dilated cardiomyopathy, mitochondrial
dysfunction, and increased female morbidity (Watson, 2010), also similar to our model.
We interpret these findings to indicate that AKAP13 acts as a “regulator of
regulators,” coordinating, either directly or indirectly, transcription factor activation to
facilitate a cardiac gene program unique to the developmental stage of the organism from
the embryo (Mayers, 2010) through adulthood. It is likely that AKAP13 acts in multiple
pathways to bring about the downstream effects highlighted in this dissertation. Here we
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showed AKAP13 acting downstream of LPA in the PKA/RhoA pathways to modulate SRF
and SRE-responsive genes. In the absence of AKAP13, PKA was decreased, and is likely
no longer able to inhibit LPA stimulation of SRF, thereby allowing SRF to be derepressed, and SRE-responsive genes to be inadvertently turned “on.” This would disturb
the usually tightly regulated transcriptional program. Additionally, reports in the literature
have shown AKAP13 regulation of Estrogen Receptor α (ERα) both indirectly through a
Cdc42-dependent mechanism, and directly through binding PKA and phosphorylating ERα
(Rubino, 1998) (Toaldo, 2015). Dysregulation of ERα would result from loss of Akap13
and may partially explain the more severe phenotype exhibited by female Akap13cKO mice.
These findings provide the first correlation between AKAP13 and a cardiomyopathy with a
severe mitochondrial phenotype. Because of this, Akap13 should be considered a candidate
gene for complex familial DCM with mitochondrial phenotypes, and a candidate gene for
sex-specific differences in heart disease. Future studies should focus on elucidating the
mechanism of AKAP13, its role in mitochondrial dynamics, sex-specific differences in
cardiomyopathy, and as a potential target for drug development and therapeutics.
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CHAPTER 4: Materials and Methods

Animal care and use. All animal studies and procedures were approved by the Office of
Animal Care and Use at the NICHD, NIH, and the ACUC at Johns Hopkins University
School of Medicine. All animal tissue harvests were performed post-mortem; euthanasia
procedures followed strict institutional guidelines.
Generation of Akap13 conditional knockout murine model. A Cre-lox deletion strategy
was used to generate Akap13cKOmice. Lox p sites were inserted as previously described
(Liu P, 2003); the Akap13 guanine nucleotide exchange factor (GEF) domain was targeted
for deletion.

Akap13cKO mice were generated by crossing Akap13Flox/Flox mice with

homozygous alpha-Myosin Heavy Chain-MerCreMer (α-MHC-MerCreMer) mice.
Tamoxifen (40mg/kg body weight) was administered for 4 weeks through tamoxifen laced
chow (Harlan Tekland) to induce cardiomyocyte-specific knockout for the α-MHCMerCreMer model. An alternative Akap13cKO was generated by using Tetracycline- on cre
(TOC); mice were given ad libitum access to doxycycline (1mg/mL) (Sigma) laced
drinking water for one to two weeks. All mice had a C57Bl6/J background strain. Assays
and imaging were conducted following cessation of tamoxifen or doxycycline treatment.
gDNA was isolated from mouse tail tissue using the Wizard® Genomic DNA Purification
Kit (Promega, Madison, WI, USA) per manufacturer’s instructions. Polymerase chain
reaction (PCR) was used for genotyping analysis as previously reported (Koide, 2015).
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Southern Blot. For confirmation of our transgenic construct in the embryonic stem cells
and in the Akap13Flox/Flox mice, we performed a Southern blot as previously reported
(Koide, 2015).
In situ hybridization, Immunohistochemistry and Immunoblot. Quantitative real time
polymerase chain reaction (qRT-PCR) was performed to assess Akap13 transcript levels
for knockdown. Low levels of message in Akap13cKO hearts compared with control mice
suggested knockdown was achieved. In situ hybridization analyses were performed as
previously described (Koide, 2015) in order to assess the distribution and knockdown of
AKAP13 in paraffin embedded 4-5µm thick slices of control and Akap13cKO mouse hearts,
respectively. Hearts were collected from euthanized mice, and fixed in 10% neutral
buffered formalin. Results substantiated those of qRT-PCR. Immunohistochemstiry (IHC)
was used to ascertain protein levels in Akap13cKO mice compared to controls. IHC was
performed with MULTIVIEW® (mouse-HRP/rabbit-AP) IHC kit (Enzo Life Sciences,
Boston, MA, USA) per manufacturer’s instructions. AKAP13 antibodies were used as
previously described (Mayers, 2010); anti-sarcomeric alpha-actinin (EA-53) (Abcam,
Cambridge, MA, USA) was used as a control. Western blot was performed essentially as
previously described (Rubino, 1998). AKAP13 and β-actin antibodies were used as
previously described (Mayers, 2010). IHC and western blot both validated knockdown of
AKAP13 protein.
RT-PCR. In order to evaluate the tissue specificity of the MCM and TOC, RNA was
isolated from Akap13cKO and control mice hearts, testes, ovaries, and livers using the
RNeasy kit (Qiagen) for evaluation by reverse transcription polymerase chain reaction
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(RT-PCR). The RNA was reverse transcribed using iScript (BioRad), followed by PCR.
Primers used were as previously described (Koide, 2015).
Magnetic Resonance Imaging. Magnetic Resonance Imaging (MRI) was performed on
Akap13cKO and control mice at baseline and with stress. Mice were anesthetized with1-2%
isoflurane and imaged with ECG, respiratory and temperature detection as described in
standard MRI methods. Dobutamine stress testing was performed after acquiring gradient
echo cine scans of the whole heart at baseline (typically 6 slices), without stress, then
scanning 2 or 3 mid-ventricle slices under stress at two dobutamine infusion rates and
comparing the ejection fractions and any wall motion abnormalities. Mice receive 0.2-0.3
mmol/kg Magnevist (Bayer HealthCare, Montville, NJ) i.v. at baseline and 0.2 mmol/kg at
initiation of dobutamine stress. After the baseline scan mice are infused with 1/20
dobutamine (Eli Lilly, Indianapolis, IND) in 0.9% saline, 5% dextrose or 5%
dextrose/0/9% saline at a dobutamine dose of 10µg/kg/min (0.010 mg/g/min) using an
infusion pump (Cole-Parmer, Vernon Hills, Il.). After the heart rate reaches a steady state
in 4-10 minutes, two or three slices, which are identical to 2-3 of the baseline slices at midventricle, are imaged. Infusion rate is increased to 40µg/kg/min (0.040 mg/g/min) and the
scans were repeated. Infusion was stopped and the mice were recovered. Cardiac
functional analysis from the cine image data was performed. A full functional analysis is
performed on the baseline data. Then for the mid ventricle slices of the baseline, low and
high dose dobutamine scans, ejection fraction and wall motion are compared.
Echocardiograpy (Echo). All animals were under general anesthesia and body
temperature was maintained at 37°C for the duration of the experiment. Animals were
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induced at 4% isoflurane maintained with 1-2% isoflurane via nosecone.

Sterile

ophthalmic ointment was applied to prevent corneal desiccation while under anesthesia.
The hair from the chest was removed using a chemical hair remover. The animal was
placed in a supine position and secured with tape and Ultrasound gel was spread on the
precordial region and the Vevo2100 (Visual Sonics, Toronto, CA) with a 40Hz transducer
was used to acquire B-mode, M-mode, aortic valve, pulmonary valve and mitral valve
visualizations. Mitral inflow recordings were obtained with the pulsed Doppler sample
volume at the level of the mitral leaflet tips during maximal opening in diastole. Tissue
Doppler recordings were measured with sample volumes at both the septal mitral annulus
and lateral mitral annulus. The cardiac wall thickness and left ventricle size were
determined by M-mode. The valves were measured with pulsed-wave Doppler mode.
Animals were recovered in a warm cage until awake and ambulatory.
Electrocardiogram (ECG). All animals were under general anesthesia and body
temperature was maintained at 37°C for the duration of the experiment. Animals were
induced at 4% isoflurane and maintained at a rate of 1.5-2% isoflurane during ECG
acquisition. Mice were placed in a supine position, and 29-gauge needle electrodes were
inserted subcutaneously into all four limbs. Six leads were continuously recorded with
Powerlab (ADInstruments, Colorado Springs, CO). Leads I and II were recorded directly
via the needle electrodes and Leads III, aVR, aVL, and aVF were calculated automatically
through LabChart 7.0 (ADInstruments) for one minute. Animals were placed in a warmed
cage until awake and ambulatory. Each signal was analyzed using LabChart 7.0 ECG
(ADInstruments) module software analysis using the Bazett formula. The QTc interval was
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analyzed using the Fridericia formula. The ECG analysis module automatically detects
PQRST onset, amplitude, and interval with default or customized detection settings.
Blood pressure. Systolic and diastolic blood pressures and Mean Arterial Pressure were
measured in conscious mice using a computerized tail-cuff non-invasive system (Hatteras
Instruments, Cary, NC) on a heated 37˚C platform. Mice were acclimated for three days
every week in order to enhance reliability and reproducibility of the blood pressure
measurements. Data obtained after acclimation period was recorded.
Histologic, light and fluorescent microscopic examination of cardiac tissues. Hearts
were collected from post-mortem Akap13cKO mice and controls, rinsed in 1XPBS, fixed in
10% neutral buffered formalin, and embedded in paraffin blocks. Paraffin-embedded 45µm slices were fixed to glass slides (with RNAse- cutting precaution) (Histoserv,
Germantown, MD, USA). Haematoxylin/Eosin (H&E) stained mid-ventricular slices
(Histoserv) were obtained from Akap13cKO mice and controls; ventricular sizes and
disrupted cardiomyocytes were quantified using ImageJ (NIH, Bethesda, MD, USA). To
estimate possible cardiac infarct and necrosis, Phosphotungstic acid-haematoxylin (PTAH)
stain for cardiac muscle fibers and collagen was performed on fixed, paraffin-embedded
slices (Histoserv). Hearts were also fixed in OCT, snap-frozen, and frozen sections were
prepared (Uniform Services University of the Health Sciences). Masson-trichrome, a
connective tissue stain, was used to measure fibrotic areas in the cardiac tissue; collagen
fibers stain blue, all other tissue stains red, and nuclei will appear black. Masson-trichrome
stain (Histoserv) was performed on paraffin-embedded slices. All images of H&E, PTAH,
and Masson-trichrome, stained sections were obtained with a Leica DMLS Binocular
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Microscope (Leica Microsystems, Germany). For quantification, at least 4 independent
images for each region of interest was used.
Apoptosis assay. To assess apoptosis in cardiac tissues, dUTP Nick End Labeling
(TUNEL) In Situ Cell Death Detection Kit, Fluorescein (Roche, Indianapolis, IN, USA)
was performed on paraffin-embedded slices per manufacturer’s instructions. Fluorescent
images were obtained using a Leica DMIRB Inverted Fluorescence Microscope (Leica
Microsystems, Germany). For quantification 4 independent images for each region of
interest were used and analyzed with ImageJ (NIH).
Transmission Electron Microscopy (TEM). Akap13cKO and control heart tissue samples
were prepared and observed as described (Wang, 2016). Image data was analyzed using
ImageJ (NIH).
Bioinformatics: Proteomics. Tissue samples were homogenized in tris-buffered saline,
followed by addition of an equivalent volume of lysis buffer (final concentrations: 1%
SDS, 0.5% NP-40, 0.5% sodium deoxycholate). Samples were frozen for 4 h at -20 °C,
transferred to 1.5 mL tubes and sonicated three times for 30 s at the lowest setting with
sample cooling on ice between pulses. Samples were then boiled for 10 min and
centrifuged to remove cell debris. Protein quantitation was performed on a 1/10 dilution of
the sample solution using the BCA assay (ThermoFisher Scientific). Fifty micrograms of
each sample were electrophoresed into the stacking portion of a 4-15% gel (MiniPROTEAN TGX, Bio-Rad), excised from the gel and processed by in-gel digestion (I’ll
get you a reference for this). Briefly, gel bands were destained in 25 mM AMB, 50%
acetonitrile (ACN, Sigma-Aldrich) at ambient temperature on a vortex platform. Gel bands
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were dehydrated in 100% ACN and incubated in 25 mM AMB, 10 mM dithiothreitol
(Sigma-Aldrich) at 56 °C for 30 min followed by alkylation with 25 mM AMB, 55 mM
iodoacetamide (Sigma-Aldrich) in darkness for 45 min at ambient temperature. Gel slices
were dehydrated in 100% ACN and rehydrated with 20 ng/μL sequencing grade modified
trypsin (Promega, Madison, WI, USA), 25 mM AMB on ice for 45 min. Excess trypsin
was removed, gel bands were washed with 500 μL of 25 mM AMB and in-gel digestion
was performed at 37 °C for 16 h. Tryptic peptides were extracted with 70% ACN, 5%
formic acid (Sigma-Aldrich) and peptide extracts were lyophilized by vacuum
centrifugation and stored at -80 °C until analysis.
Samples were resuspended in 25 mM ammonium bicarbonate (Sigma Aldrich, St. Louis,
MO) and were analyzed through five consecutive injections by LC-MS/MS on a nanoflow
LC system (Easy-nLC 1000, ThermoFisher Scientific, San Jose, CA) coupled online with a
Q Exactive MS (ThermoFisher Scientific). Samples were resolved on a 100 μm I.D. × 360
μm O.D. × 20 cm long capillary column (Polymicro Technologies, Phoenix, AZ), which
was slurry packed in house with 5 μm, 100Å pore size C-18 silica-bonded stationary phase
(Magic C18AQ, Bruker). Following pre- and analytical column equilibration, each sample
was loaded onto a 2-cm reversed-phase (C-18) pre-column (ThermoFisher Scientific) at 3
μL/min at 3x the injection volume with mobile phase A (0.1% formic acid in water).
Peptides were eluted at a constant flow rate of 200 nL/min by development a linear
gradient of 0.33% mobile phase B (0.1% formic acid in acetonitrile) per min for 120 min
and then to 95% mobile phase B for an additional 15 min. The columns were washed for
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15 min at 95% mobile phase B and then quickly brought to 100% mobile phase A for the
next sample injection.
The MS was configured to collect broadband mass spectra (m/z 375-1800) in profile mode
using the lock mass feature for the polydimethylcyclosiloxane (PCM) ion generated in the
electrospray process (m/z 445.12002). Mass spectrometric conditions were set as follows:
electrospray voltage, 1.7 kV; no sheath and auxiliary gas flow; capillary temperature, 250
°C; S-Lens RF level, 60%; resolution, 70,000 at m/z 200. The ion selection threshold for
the broadband scan was set at 1e6 with a maximum ion accumulation time of 50 ms. The
ten most abundant ions were selected for MS/MS with the following settings: ion
threshold, 1e6; intensity threshold, 5e3; maximum ion accumulation time, 200 ms;
resolution, 17,500 at m/z 200; isolation window, 3 m/z; dynamic exclusion, 40 s; and a
normalized collision energy (NCE) of 25.
Tandem mass spectra were searched against the SwissProt mouse protein database
(downloaded on 09/25/2015, 16,719 sequences) from the Universal Protein Resource
(www.uniprot.org) using Mascot Daemon/Server (v.2.3.2/v.2.3, Matrix Science Inc.,
Boston, MA) using the automatic decoy search option. The data were searched with a
precursor mass tolerance of 10 ppm and a fragment ion tolerance of 0.6 Da. Cysteine
carbamidomethylation (m/z 57.021464) was set as a fixed modification and methionine
oxidation (m/z 15.994915) was set as a dynamic modification. A maximum of two missed
tryptic cleavages were allowed. Identified peptides (PSMs, peptide spectral matches) were
filtered using an ion score cutoff of 33 resulting in a false peptide discovery rate of less
than 1% for all peptides identified (determined from the decoy database search). PSMs
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whose sequence mapped to multiple protein isoforms were grouped as per the principle of
parsimony. Results for each sample were normalized to the sample with the lowest total
PSMs for the five replicate injections/analyses and protein abundance differences were
determined by spectral counting, where the total PSMs identified for a given protein
reflects overall abundance. For sample comparisons, statistical analyses for the enrichment
of specific proteins among differentially expressed proteins were performed utilizing a zstatistic test on the log2-transformed spectral count ratios from normalized data. False
positives (q values, FDR) were estimated using the R package “q value”. These data were
analyzed using Ingenuity Pathway Analysis (Qiagen), Metacore (Thomson Reuters, New
York, NY, USA), and Pathway Studio (Elsevier, Amsterdam, Netherlands).
Adult cardiomyocyte isolation and protein and RNA extraction. Adult cardiomyocytes
were isolated from Akap13cKO mouse hearts and control hearts using an enzymatic
digestion method (Cellutron, Baltimore, MD, USA). Cells were maintained in AS media
(Cellutron), and were plated at the manufacturer’s recommended cell density at least 6
hours before imaging. For protein and RNA isolation, adult cardiomyocytes were
maintained in suspension culture for 30min-1 hour. Cells were pelleted by centrifugation at
1100rpm, and the AS medium was removed. Cells were re-suspended in either RIPA
buffer (Invitrogen) supplemented with 4% protease and phosphatase inhibitors (Qiagen)
for protein isolation, or Buffer RLT supplemented with β-mercaptoethanol per
manufacturer’s instructions (RNeasy, Qiagen, Valencia, CA, USA) for RNA isolation. For
western blot, protein concentration was confirmed by BCA analysis (ThermoFisher);
500ng-1ug of protein lysate was loaded per lane. Immunoblotting essentially followed our
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previously reported method (Rubino, 1998) except for the use of NuPAGE® Tris-Acetate
gels and buffer system (ThermoFisher, Halethorpe, MD, USA) in lieu of the Tris-glycine
system. RNA was isolated using the RNeasy kit. Manufacturer guidelines were followed
for isolation and purification of RNA.
Bioinformatics: RNAseq. RNA from mouse hearts were isolated as described above.
RNA Integrity Number (RIN) was assessed with a Bioanalyzer 1000 RNA chip (Agilent,
Santa Clara, CA, USA); a minimum RIN value of 8.5 was established. Ribosomal rRNA
removal, poly-A enrichment, and reverse transcription and library preparation were
performed as previously described (Nuno L. Barbosa-Morais, 2012). Paul H. Driggers,
PhD, kindly generated a differentially expressed gene list from the raw data files. These
data were analyzed using Ingenuity Pathway Analysis (Qiagen), Metacore (Thomson
Reuters, New York, NY, USA), and Pathway Studio (Elsevier, Amsterdam, Netherlands).
Cell Culture, cytoimmunofluorescence, confocal imaging, and quantitation. H9c2 cells
were purchased from ATCC (Manassas, VA, USA) and maintained in DMEM medium
(ATCC, Manassas, VA, USA) supplemented with 10% FBS, and 1% penicillinstreptomycin (Invitrogen). Staining procedures were followed as previously reported
(Mayers, 2010). H9C2 cells and
Mitochondrial assays. Primary adult cardiomyocytes and H9c2 cells were imaged to
assess the number of mitochondria and in mitochondrial membrane potential in primary
adult cardiomyocytes from Akap13cKO mice and control mice, and in Akap13 siRNA
knockdown (H9c2 cells). Mitochondrial membrane potential was also assessed by the JC-1
biochemical assay kit (ThermoFisher)
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Immunoblot. Intact mitochondria were obtained using the Mitochondrial Isolation Kit
(ThermoFisher). Mitochondria were then lysed following the manufacturer guidelines. For
protein isolation from tissue, hearts were collected post-mortem and snap frozen in liquid
nitrogen; snap frozen tissues were stored at -80°C. Tissue lysates were prepared the
TissueRupter homogenizer (Qiagen)
Biochemical analyses. RhoA and PKA activity were analyzed in tissue lysates from
Akap13cKO mouse hearts and control hearts. To quantify active RhoA in the Akap13cKO
mouse hearts, Rho G-LISA (Cytoskeleton) was performed per the manufacturer’s
instructions. PKA activity was assessed using PKA activity assay Kit (ThermoFisher).
qRT-PCR. For analysis of mRNA transcripts of key genes, quantitative real time
polymerase chain reaction (qRT-PCR) was performed as described in the literature (Koide,
2015). RNA was extracted from mouse hearts or H9c2 cells, where appropriate, with
RNeasy (Qiagen). RNA was reverse transcribed to cDNA using iScript (BioRad). SYBR
Green (BioRad) was used for RT-qPCR analysis per manufacturer’s directions.
Statistical Data Analyses. Mean levels of test outcomes were compared by genotype and
sexes using one-way ANOVA with Bonferroni adjustment for multiple comparisons and
T-Tests where appropriate. These analyses were performed using the SAS (Statistical
Analysis System) software version 9.3 (Cary, NC, USA). Student’s t-test used for
statistical analyses; (* where p<0.05, ** where p<0.01). Student’s t-test, Mann-Whitney
test for median comparison, and Chi-squared tests were used for statistical analyses as
appropriate; * where p<0.05, ** where p<0.01). Biological replicates (n) were used in
testing. Analyses are combined sex unless otherwise noted.
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Primers List:
PCR primers:
5F 5’- GCG GAA GAA GGA GTC TCT TG -3’
7R 5’- TCA CCT TTG GTA CAT TGC AG -3’
8R3 5’- ATC GAC TTG CTA TCT GTC C -3’
MerCreMer-F: 5’- AGG TGG ACC TGA TCA TGG AG -3’
MerCreMer-R: 5’- ATA CCG GAG ATC ATG CAA GC -3’
TOC-F: 5’- GGC GCG GCA ACA CCA TTT TT -3’
TOC-R: 5’- TCC GGG CTG CCA CGA CCA -3’
RT-qPCR primers:
mAKAP13-F: 5’-TGG ATG AGC TGA TCA GTA TC- 3’
mAKAP13-R: 5’- TTG ACA GAC TGG TTG TGC TG-3’
m18S-F: 5’-CTT AGA GGG ACA AGT GGC G-3’
m18S-R: 5’-ACG CTG AGC CAG TCA GTG TA-3’
mGAPDH-F: 5’-GTT TGT GAT GGG TGT GAA CCA C-3’
mGAPDH-R: 5’-CTG GTC CTC AGT GTA GCC CAA-3’
Srf-F: 5’- CAC GAC CTT CAG CAA GAG GA-3’
Srf-R: 5’- CAA AGC CAG TGG CAC TCA TT-3’
PKN-F: 5’ –GAG AAG GCT ACT GCG GAG GA-3’
PKN-R: 5’ –CGG CCA CAA AGT CGA AAT C-3’
Opa1-F: 5’- TGA CAA ACT TAA GGA GGC TGT G-3’
Opa1-R: 5’- CAT TGT GCT GAA TAA CCC TCA A-3’
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APPENDIX A

The following pages of this appendix contain supplementary figures and tables
referenced in this dissertation. The nomenclature for supplementary figures includes an “S”
in the figure code. The nomenclature for supplementary tables includes “ST” in the table
code.
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Figure S.1| Heart Disease Statistics. In the United States of America, heart disease is the
number one cause of death in women. In 2010, it was estimated that one in four women
died of cardiovascular disease (NHLBI, 2010).
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Figure S.2| AKAP13 in adult myocardium. a) Immunohistochemistry, Adult human
myocardium showed strong protein staining for AKAP13. b) Enlargement of previous
showed a striated AKAP13 banding pattern. c) Immunohistochemistry, Adult mouse
myocardium with Pre-immune anti-sera. d) Immunohistochemistry, Adult mouse
myocardium with anti-AKAP13 demonstrated strong AKAP13 presence.
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Figure S.3| Establishment and validation of Akap13 conditional knockout. a) Targeting
construct and floxed allele, A Cre-lox recombination strategy was used for targeted
deletion of the GEF domain. The dashed lines show the areas of recombination between
the WT allele and the targeting construct which resulted in the Neo floxed allele. FRT sites
flanked the neomycin cassette and LoxP sites flanked the sequence designated for deletion,
including exons 24 and 25 and adjacent regions. b) Southern Blot, BsmI digestion of ES
Cell gDNA for validation of the neo floxed allele. c) Polymerase Chain Reaction (PCR),
PCR validation of neo floxed allele; the desired PCR product size for the neo floxed allele
was 4.2kb. d) Sequencing Analysis, sequence file shown is for ES cell gDNA validation of
LoxP. e) Graphic showing LoxP sequence and directionality. f) Sequencing Analysis,
sequence file shown for adult mouse gDNA validation of LoxP. Dotted, yellow line shows
LoxP.
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Figure S.4| In vitro validation of recombination. a) pCAG-Cre:GFP vector used for
transfection of competent cells. b) Validation of targeting vector (TV) and pCAGCRE:GFP vector through fluorescence. C) PCR, validation of desired recombination event.
The PCR product for the mutant (floxed) allele is 1.7kb whereas the WT allele is 2.0kb.
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Figure S.5| Blood Chemistry demonstrated multi-organ dysfunction in global Akap13
(+/-) mice. a) Blood levels of Creatine Kinase (CK) indicated muscle damage in the
Akap13 (+/-) mice compared to control mice (p<0.05). Historically, CK blood levels were
used to diagnose myocardial infarction (MI).
b) Lactate Dehydrogenase (LDH) was increased in Akap13 (+/-) mice compared to control
mice which suggested tissue damage (p<0.05). c) Alanine Aminotransferase (ALT) blood
levels were elevated in Akap13 (+/-) mice compared to control mice (p<0.05). This
indicated liver function may have been impaired in the haploinsufficient mice. d) Blood
urea nitrogen (BUN) levels suggested kidney function was impaired in the Akap13 (+/-)
mice compared to control mice (p=0.06).
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Figure S.6|Southern Blot showed mutant allele in Akap13cKO-MCM mouse hearts. a)
Schematic diagram showing Cre-recombination of the floxed allele, induced by tamoxifen
treatment, to produce the cardiomyocyte specific mutant allele. Red arrows indicate LoxP
site(s). Yellow arrow indicates the FRT site. b) Southern blot showed the mutant (1.3kb)
band in EcoRV digested gDNA from Akap13cKO-MCM mouse hearts, but was not readily
visible in the Akap13Het-MCM hearts.
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Figure S.7|Genotyping. a) PCR of mouse gDNA showed neo floxed (3.6kb), floxed (1.7
kb) and WT (2.0 kb) bands. b) PCR of mouse gDNA showed Cre positive bands (440bp).
c) PCR of mouse gDNA showed homozygous floxed bands (1.7kb), homozygous WT
bands (2.0kb), and heterozygous (Flox/WT) bands.
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Table ST.1|Comparison of controls by Magnetic Resonance Imaging (MRI). Here we
showed W/W, MCM+ mice given tamoxifen compared with control mice expressing
MCM. No statistical differences were observed with Magnetic Resonance Imaging (MRI)
(p>0.05).
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Table ST.2|Comparison of controls by MRI. Here we showed F/F, MCM- mice given
tamoxifen compared with F/F, MCM+ mice on control chow. No statistical differences
were observed with Magnetic Resonance Imaging (MRI) (p>0.05).
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Table ST.3|Comparison of controls by electrocardiogram (ECG). Here we showed
there were no statistical differences between types of control mice: F/F, MCM- given
tamoxifen chow and F/F, MCM+ given control chow (p>0.05).
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Figure S.8| TUNEL showed no increase in apoptosis in Akap13cKO-MCM mouse hearts. a)
Monkey ovary was used as an intrinsically positive TUNEL control. b) Heart tissue
sections treated with DNaseI for positive TUNEL control. c) Akap13cKO-MCM mouse hearts
showed no increase in apoptosis.
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Figure S.9| Sarcomeric disruption and increased lipid inclusions in Akap13cKO mouse
cardiac tissue. Electron microscopy revealed significant disruption of the cardiac
sarcomeres and ultrastructure. Lipid inclusions were also seen with increased frequency in
Akap13cKO mouse cardiac tissue compared to control mouse cardiac tissue.

184

Figure S.10| Increased lipid droplets in Akap13cKO mouse cardiac tissue. Electron
micrograph, showed increased lipid droplets and blind ended sarcomeres.
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Table ST.5| Resting MRI Summary Table for Akap13Het-MCM mice. No significance was
seen when Akap13Het-MCM mice where analyzed as a group.
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Table ST.6| Stress MRI Summary Table for Akap13Het-MCM mice. Significant differences
are seen in female Akap13Het-MCM mice only.
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Table ST.7| Resting MRI Summary Table for right ventricular function Top) statistical
differences in right ventricular function between Akap13cKO-MCM and control mice. Bottom)
No statistical differences were seen in Akap13Het-MCM mice compared to control mice.
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Table ST.8| Resting MRI Summary Table for right ventricular function in Akap13cKOMCM mice. a) Overall, Akap13cKO-MCM mice showed significant differences in all right
ventricular measurements compared to control mice. b) Summary of right ventricular
function stratified based on sex.
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Figure S.11| E- and A-waves indicate mitral inflow. Normal (left) and pathologic
(middle and right) E- and A-waves are shown. (European Journal of Echo., 2009)
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Figure S.12| Diagram showing normal and pathologic filling patterns of the left
ventricle. Diagram showing grade I-IV pathologic filling patterns
(https://123sonography.com/ebook/assess-diastolic-function).
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Figure S.13| Compensatory hypertrophy in Akap13cKO-MCM mice ≥8 weeks postrecombination. a) Akap13cKO mice (n=4) <8 weeks post-recombination showed dilated left
ventricles. b) Akap13cKO-MCM mice ≥8 weeks post-recombination showed compensatory
hypertrophy.
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Figure S.14| No changes in blood pressure or mean arterial pressure (MAP).
Akap13cKO-MCM mice (n=6) showed no significant differences in systolic pressure, diastolic
pressure or MAP compared to control mice (n=8) (p>0.05). Mice were awake during
testing and had been habituated to the test for 2-3 days before final evaluation. Blood
pressure was assessed using a tail blood pressure cuff designed for rodents. Student’s t-test
used for statistical analyses.
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Figure S.15| Tachycardia in awake Akap13cKO-MCM mice. Akap13cKO-MCM mice (n=6) had
increased heart rate (tachycardia) compared to control mice (n=8). Mice were awake
during testing and had been habituated to the test for 2-3 days before final evaluation.
Heart rate was assessed using a tail cuff designed for rodents.
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Figure S.16| Phosphotungstic acid-haematoxylin (PTAH) stain showed dysmorphic
cardiomyocytes.
a) Control mouse heart tissue stained with PTAH. Cardiac muscle cells appear purple.
b) Akap13cKO-MCM mouse heart tissue stained with PTAH showed granular and irregular
staining pattern in the cardiac muscle cells.
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Figure S.17| Trichrome stain showed increased collagen with time post-recombination
in Akap13cKO mice. a) Akap13cKO mice <8 weeks post-recombination showed dilated left
ventricles with little collagen deposition (blue) with trichrome stain. b) Akap13cKO-MCM
mice ≥8 weeks post-recombination showed compensatory hypertrophy with increased
collagen deposition (blue) with trichrome stain.
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Table ST.9| Proteomics summary table. Proteomics analysis, cardiac tissue from 5 month
old control (n=3) and Akap13cKO (n=3) mice was used for assessing changes in the
Akap13cKO proteome. Pathway analysis demonstrated pathological changes in major
mitochondrial processes (oxidative phosphorylation), fusion proteins (MFN1) and changes
to the cytoskeleton. Additionally, changes were seen in PKA (RIIA).
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Table ST.10| RNAseq revealed signs of heart failure and dysregulation of
transcription factors in Akap13cKO-MCM mice. RNAseq, Next generation sequencing of
RNA isolated from 5 month old control (n=3) and Akap13cKO-MCM (n=3) pathway
enrichment analysis identified signs of heart failure (increased ANP, fetal gene response)
and transcription factor dysregulation (AK4 and E2f1) in the Akap13cKO-MCM mice.
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Figure S.18| Mef2c transcript levels increased in Akap13cKO-MCM mouse hearts. RTqPCR, Preliminary quantitative analysis of MADS box transcription enhancer factor 2,
polypeptide C (Mef2c) transcript levels showed upregulation of Mef2c in Akap13cKO
mouse hearts suggesting a cardiac fetal gene response as seen with proteomic and
transcriptomic analyses.
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Table ST.11| Cardiac proteomic analyses revealed signs of heart failure in Akap13cKOMCM mice. Cardiac proteomic analyses also showed increased signs of heart failure
including increased complement and growth factors. Some mitochondrial proteins
(Higd1a) were also significantly increased which suggested that mitochondrial proteins
were not all decreased, rather, specific pathways were being affected.
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Figure S.19| AKAP13 localizes to actin in H9c2 cells. H9C2 (rat cardiomyoblasts) dual
labeling showed AKAP13 (green) co-localization (yellow) to actin filaments (red); the
nucleus was stained with DAPI (blue).
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Figure S.20| Control and All Stars Negative (ASN) showed no changes in Akap13
transcript levels. a) RT-qPCR, Endogenous levels of Akap13 mRNA transcripts were
knocked down using small interfering RNA (siRNA). (p<0.001). Student’s t-test used for
statistical analyses. b) RT-qPCR, Endogenous levels of Akap13 mRNA transcripts were
quantified in control (no transfection) and ASN transfected H9c2 cells. No changes in
endogenous Akap13 transcripts were observed (p>0.05). Student’s t-test used for statistical
analyses.
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Figure S.21| Akap13 knockdown. RT-qPCR, Endogenous levels of Akap13 mRNA
transcripts were knocked down in H9c2 cells using small interfering RNA (siRNA).
(p<0.001). All Star’s Negative (ASN) transfected H9c2 cells were used for control.
Student’s t-test used for statistical analyses.
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Figure S.22| Overexpression of AKAP13 activated SRE-luciferase. Upper)
Overexpression of AKAP13 showed increased fold-activation of SRE-luciferase at 125ng,
250ng, and 375ng of AKAP13, consistent with published data (Mayers, 2010). Lower)
Overexpression of AKAP13 domains showed increased SRE-luciferase activation with the
GEF domain more so than the nuclear hormone receptor interacting domain (NRID) with
lysophosphatidic acid (LPA) treatment.
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Figure S.23| Dose-response seen with overexpression of AKAP13 with robust CRE-luc
activation. Overexpression of AKAP13 in H9c2 cells showed a robust increased foldactivation of CRE-luciferase at 125 ng and especially 250 ng AKAP13 (8-fold activation).
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APPENDIX B

The following pages of this appendix contain tables for the TetOnCre (TOC)
mouse model. Data are provided where available. This second Cre was introduced later
during the project, so all assays that were performed using the MCM mouse model were
not necessarily performed with the TOC mouse model. Tables are included here for
completeness.
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Resting MRI: TOC Model
LVEF
EDVI
ESVI
EDMI
ESMI

Akap13 cKO-TOC
59.02
%
2.13
µL/g
0.87
µL/g
3.68
mg/g
3.68
mg/g

Control
67.05
%
1.88
µL/g
0.622
µL/g
3.46
mg/g
3.39
mg/g

p-value
0.0042
0.068
0.0062
0.039
0.040

Resting MRI: TOC Model. Akap13cKO-TOC (n=7) and Control (F/F, TOC+; no treatment;
and F/F, TOC- with doxycycline treatment) (n=5). Left Ventricular Ejection Fraction
(LVEF); End-Diastolic Volume Index (EDVI); End-Systolic Volume Index (ESVI); EndDiastolic Mass Index (EDMI); End-Systolic Mass Index (ESMI).
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Resting MRI: TOC Model- Female
LVEF
EDVI
ESVI
EDMI
ESMI

Akap13 cKO-TOC
59.54
%
2.21
µL/g
0.90
µL/g
3.64
mg/g
3.63
mg/g

Control
69.8
%
1.99
µL/g
0.60
µL/g
3.62
mg/g
3.48
mg/g

p-value
0.030
0.077
0.015
0.88
0.79

Resting MRI: TOC Model- Female. Akap13cKO-TOC (n=4) and Control (F/F, TOC+; no
treatment; and F/F, TOC- with doxycycline treatment) (n=4). Left Ventricular Ejection
Fraction (LVEF); End-Diastolic Volume Index (EDVI); End-Systolic Volume Index
(ESVI); End-Diastolic Mass Index (EDMI); End-Systolic Mass Index (ESMI).

Resting MRI: TOC Model- Male
LVEF
EDVI
ESVI
EDMI
ESMI

Akap13 cKO-TOC
61.47
%
1.91
µL/g
0.75
µL/g
3.50
mg/g
3.56
mg/g

Control
63.84
%
1.92
µL/g
0.70
µL/g
3.32
mg/g
3.37
mg/g

p-value
0.85
0.78
0.86
0.83
0.63

Resting MRI: TOC Model- Male. Akap13cKO-TOC (n=8) and Control (F/F, TOC+; no
treatment; and F/F, TOC- with doxycycline treatment) (n=4). Left Ventricular Ejection
Fraction (LVEF); End-Diastolic Volume Index (EDVI); End-Systolic Volume Index
(ESVI); End-Diastolic Mass Index (EDMI); End-Systolic Mass Index (ESMI).
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